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Abstract 
 
We previously found that enteral nutrition with diets containing elevated 
levels of eicosapentaenoic acid (EPA; 20:5 n-3) reduced the number of 
neutrophils in bronchoalveolar lavage fluid and improved clinical outcome of 
patients with or at risk for adult respiratory distress syndrome (ARDS).  We have 
also shown that the treatment of the neutrophil-like cell line, HL-60, with EPA can 
induce apoptosis.  It is not known, however, if the addition of EPA to the diet 
would result in similar occurrences in neutrophils.   
It has been suggested that the use of diets enriched with stearidonic acid 
(SDA; 18:4 n-3) may provide a novel source of n-3 fatty acids while offering 
similar beneficial effects on health as diets containing EPA.  Therefore,  we 
examined whether dietary SDA can be used as a precursor to increase EPA 
content in liver tissue.   
It is well known that endotoxin increases neutrophil lifespan and that this 
may be important in maintaining innate immune response.  The second part of 
this study incorporated the use of glycogen-elicited peritoneal neutrophils from 
the rat to examine the effect of dietary intervention with n-3 fatty acids (either 
EPA or SDA) on constitutive and endotoxin induced neutrophil survival.  Male 
Long-Evans rats (n=18) were randomly divided into 3 dietary groups and fed a 
modified US-17 diet providing 200kcal/kg/day and containing 2% oleic acid (OA; 
18:1 n-9) (n=6), 1% EPA/1% OA (n=6), or 1% SDA/1% OA (n=6) for 2 weeks.   
Liver phospholipids were analyzed using gas chromatography and neutrophil 
lifespan was evaluated using flow cytometry.   
Dietary supplementation with EPA significantly increased the 
concentration of EPA and docosapentaenoic acid (DPA, 22:5n3), but not 
docosahexaenoic acid (DHA, 22:6n3) in liver tissue as compared with animals 
fed OA.  Dietary supplementation with SDA also increased tissue contents of 
EPA and DPA, but not DHA as compared with OA fed controls.  The increase in 
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tissue EPA was about one-half as effective in animals fed a diet containing SDA 
as those fed EPA.  SDA was about two-thirds as effective as EPA at increasing 
tissue DPA content.  These results indicate that, when fed at current dietary 
levels, SDA can increase the incorporation of EPA and DPA into the membrane 
phospholipids of liver tissue in a similar manner to dietary EPA.  This provides 
evidence that SDA may provide an alternative to EPA for increasing tissue levels 
of EPA and DPA, but not DHA. 
Flow cytometry analysis of neutrophils following 20h incubation in either 
presence or absence of endotoxin indicated that diet did not significantly affect 
constitutive or endotoxin-mediated neutrophil survival when fed at current levels.  
There was a non-significant trend towards an increase in both constitutive 
viability and endotoxin mediated cell survival (p=0.069) in both SDA and EPA fed 
animals as compared with control animals that were fed OA.  While these results 
do not fully explain the role that EPA or SDA play in reducing neutrophil influx 
during ARDS, they do provide evidence that it is not through an increase of 
neutrophil apoptosis or an attenuation of the neutrophil response to endotoxin.  
These findings may indicate the importance of dietary EPA for maintaining host 
immune response, while providing beneficial effects in regards to inflammation.  
Because of similar action between dietary EPA and SDA these results might also 
provide further proof as to the potential for dietary SDA to be used as an 
alternative for dietary EPA. 
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I. Introduction 
 
Many studies have implicated the importance of the omega 6 (n-6) and 
omega 3 (n-3) families of fatty acids in their ability to affect a number of 
pathophysiological conditions. Both families of PUFAs have exhibited the ability 
to affect a variety of disease states such as, arthritis, coronary artery disease, 
cancer and acute lung injury (ALI)[1-5].  There have been several studies that 
implicate the role of PUFAs, especially members of the n-6 family, as regulatory 
factors for programmed cell death, or apoptosis. This may be particularly 
important in inflammatory diseases where the products of fatty acid metabolism, 
the eicosanoids, have been shown to activate inflammatory cells such as 
neutrophils[6] and increase their lifespan[7].     
Neutrophils are the first line of defense in the response to bacterial infection. 
These immune cells are equipped with receptor sites that can detect components 
of bacteria such as endotoxin, which has been shown to attract and activate 
neutrophils[8].  Neutrophil activation by endotoxin has a wide variety of effects 
including; an increase in cell lifespan, the release of cytotoxic compounds, and 
the increased synthesis of eicosanoid products.  The accumulation of activated 
neutrophils in the lung is an important feature in the development of ARDS[9].  
Excessive neutrophil recruitment, activation, and release of their cytotoxic 
granules can lead to severe tissue damage in the lung. Neutrophil mediated 
tissue damage results in fluid accumulation and decreased gas exchange.  This 
damage often results in the transformation of the lung into a non-compliant, end 
stage organ.  Effective clearance of neutrophils from the lung while containing 
granule release is vital in the resolution of ARDS.  This clearance is dependent 
on neutrophil apoptosis and the recognition of apoptotic bodies by resident 
macrophages[9-11].  
Eicosanoids formed from the n-6 fatty acid arachidonic acid (AA, 20:4 n-6) 
are potent chemoattractants of neutrophils, and have also been correlated with 
an observed increase in neutrophil lifespan[12].  AA is found in abundance in 
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terrestrial food sources and is readily stored in the phospholipid portion of the cell 
membrane. The products of AA metabolism are the potent pro-inflammatory 
series-4 leukotrienes and the series-2 prostaglandins. The leukotrienes, 
particularly leukotriene B4, has been the focus of interest in incidence of 
inflammatory diseases and adult respiratory distress syndrome (ARDS)[4] 
because of its ability to attract neutrophils and alter their lifespan.   
Conversely, there has been much data supporting dietary intervention with 
members of the n-3 family of PUFAs, such as eicosapentaenoic acid (EPA, 20:5 
n-3) or docosahexaenoic acid (DHA, 22:6 n-3), both of which are found primarily 
in fish oil, having suppressive effects on inflammation and attenuating tissue 
damage in conditions such as ARDS.  This effect is attributed to a reduction of 
membrane phospholipid AA, and the products of EPA metabolism, e.g. the 
series-3 prostaglandins and the series-5 leukotrienes, which are on a scale of 30 
fold less active than their n-6 derived cousins[13].  The ability of EPA to alter the 
concentrations and types of mediators present in an inflammatory response is 
apparent in several studies involving septic shock and ARDS[4;14;15] .   Clinical 
trials have shown that ARDS patients receiving nutritional support with a high fat 
low carbohydrate diet containing fish oil as a major contributor of calories had 
significantly improved outcomes as compared with those given a traditional corn 
oil based nutritional formula.  These effects were correlated with lower LTB4 
concentration and a decrease in the number of neutrophils present in 
bronchoalveolar lavage (BAL) fluid[15].      
The effects of n-3 fatty acids in supportive therapy and disease prevention 
have led to recommendations from the American Heart Association for an 
increase in consumption of fatty fish and fish oil[16].   Unfortunately, due to a limit 
on natural fish stocks, new dangers associated with fish consumption due to 
environmental pollutants, and a resistance to the incorporation of fish into the 
established western diet these recommendations have been left largely 
unmet[17].  This has driven a new interest in identifying and developing 
alternative sources of n-3 fatty acids, particularly those that would increase tissue 
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levels of EPA efficiently when consumed at moderate levels.  Recent 
development of genetically modified canola seeds that produce stearidonic acid 
(SDA, 18:4 n-3)[18] appear to be promising for this purpose.   
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II. Rationale and Significance of Study 
 
It has been suggested that critically ill patients fed nutritional formulas 
containing high levels of n-6 fatty acids should be avoided, as excessive 
release of n-6 metabolites, particularly those derived from AA, may lead to a  
hyper-inflammatory condition that has been linked to the development of 
systemic inflammatory response syndrome and ARDS[4;19].  Dietary AA has 
been shown to increase membrane phospholipid content of AA in several 
tissues and cell types.  Further, increased membrane phospholipid AA has 
been associated with an increased production of pro-inflammatory 
eicosanoids from stimulated peritoneal cells (i.e., macrophages, mast cells, 
neutrophils)[20].  During conditions such as ARDS, combined endogenous 
and exogenous factors such as cytokines and bacterial endotoxin stimulate 
cPLA2 mediated AA cleavage from cell membrane phospholipids, resulting in 
an up-regulation  of synthesis and extracellular release of products of 
cyclooxygenase (COX) and lipoxygenase (LO) metabolism from immune 
cells[11].   Products of COX and LO metabolism of AA have been shown to 
be potent chemoattractants and activators of inflammatory cells[21;22].  In 
particular, leukotriene B4, a product of LO metabolism of AA, has been 
implicated as a neutrophil attractant and anti-apoptotic factor[12].    
Neutrophils play a critical role in inflammation and tissue damage 
associated with inflammatory diseases such as ARDS[11].  Alternatively, the 
use of n-3 PUFAs, such as EPA from fish oil, has long been recognized as 
being beneficial because of the ability of EPA to decrease AA accumulation in 
circulating blood and tissue[23;24].    Incorporation of EPA at the expense of 
AA has been associated with a decrease in pro-inflammatory eicosanoid 
synthesis[25].  Feeding diets that contain n-3 fatty acids from fish oil have 
also been associated with an attenuation of symptoms of sepsis and ARDS in 
humans and animal models[4;26]. 
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The effect of n-3 fatty acids on altering the products of eicosanoid 
metabolism has been shown to significantly improve patient conditions in a 
number of disease states of the lung[27].  Studies have shown that LTB4 is an 
active mediator for neutrophil recruitment during pleural cavity inflammation, 
as well as in inflammatory lung diseases[28;29].  Work from our laboratory 
has demonstrated a reduction in levels of pro-inflammatory eicosanoid 
products as well as a decrease in neutrophil accumulation in bronchoalveolar 
lavage (BAL) fluid of ARDS patients fed enteral nutrition formulas containing 
n-3 fatty acids from fish oil[14;30].  However, these studies did not examine 
whether reduced neutrophil counts were due to an increase in apoptosis, or 
through a reduction of neutrophil chemotaxis.  To address this question our 
laboratory examined the effect that coincubation with EPA would have on the 
lifespan of the promyelocytic human leukemia cell line, HL-60[31].  These 
studies found that direct treatment of HL-60 cells with EPA could significantly 
reduce cell viability through an increase in apoptosis.  Using various inhibitors 
of AA metabolism, the importance of AA-derived eicosanoid products in the 
regulation of apoptosis in HL-60 cells was demonstrated[32].   
Taken together, data from clinical trials and experiments with the HL-60 
cell line suggest that dietary n-3 PUFAs may act by attenuating the increase 
in neutrophil lifespan associated with endotoxin activation through an 
increase in apoptosis; thereby, decreasing the number of neutrophils 
observed in BAL fluid of patients with ARDS receiving nutritional treatment 
with n-3 PUFAs.  Further, the altered products of eicosanoid formation are 
responsible for this decrease in lifespan.  However, due to limitations and 
different findings between immortalized HL-60 cells and neutrophils it is 
important that we examine this hypothesis in the neutrophil.  The use of 
neutrophils from animals pre-fed modified US-17 diets enriched with EPA will 
allow us to determine the effect of pre-loading membrane phospholipids with 
EPA has on lifespan in either inactivated basal, or endotoxin activated 
neutrophils.     
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Many studies have suggested that the addition of n-3 fatty acids to the diet 
can have numerous beneficial effects[33].  Although these findings and 
subsequent recommendations from the American Heart Association have, 
until recently, been impractical because of supply and safety concerns of 
natural fish stocks[16;17].  The development of canola plants that accumulate 
SDA in their seeds[18] might provide a twofold benefit.  First, this may offer a 
practical strategy for providing a dietary source of EPA without the supply 
limits and safety concerns that surround an increased intake of dietary fish oil.  
Second, in situations where it is desirable to provide dietary EPA as 
therapeutic support for critical care patients, an enteral formula containing 
modified canola oil would most certainly be a cost effective alternative as 
compared with diets relying on EPA derived from fish oil.  This strategy is still 
in question, as previous work with another n-3 fatty acid, α-linolenic acid 
(ALA, 18:3 n-3), has indicated that the enzymatic fatty acid desaturation and 
elongation pathway responsible for the conversion to longer chain PUFAs 
might be too inefficient for the use of precursor fatty acids to increase tissue 
EPA content[18;34;35] .  However, dietary SDA is the metabolic product of 
the ∆-6 desaturase enzyme action on ALA.  It has been long held that ∆-6 
desaturase is the rate limiting step in fatty acid metabolism; thus, the 
efficiency of conversion and storage of SDA as EPA may be greater than that 
observed in experiments that fed ALA[18]. 
There have been relatively few studies that compare feeding diets 
enriched with SDA to diets rich in EPA, and most of the studies involving 
these fatty acids have been designed using oil blends that contain high levels 
of EPA and SDA[36-38].  In light of this, comparing the effect of feeding diets 
containing purified SDA ethyl esters on altering tissue phospholipid fatty acid 
profiles with the effects observed when feeding a diet containing purified EPA 
ethyl esters may provide valuable insight into the potential for SDA to be used 
as a precursor molecule for increasing EPA levels in membrane 
phospholipids.  Further, this experimental design will allow us to compare the 
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effects of purified SDA ethyl esters with that of purified EPA ethyl esters on 
neutrophil lifespan and apoptosis rates during endotoxin activation.  
The hypotheses of this study are twofold; first, that diets supplemented 
with SDA ethyl ester may provide a means to increase EPA content in liver 
phospholipids, and that this increase will be similar to those observed in 
animals fed a diet containing EPA.   Second, that dietary supplementation 
with SDA or EPA will impact the regulation of constitutive and endotoxin-
induced survival in neutrophils by influencing the rate of apoptosis in both cell 
states. 
The current study design will utilize glycogen-elicited neutrophils from 
male Long-Evans rats that were pre-fed diets enriched with purified EPA or 
SDA ethyl esters.  Harvested neutrophils will be incubated overnight in either 
the presence or absence of bacterial endotoxin to induce an activated cell 
state similar to that seen in models of sepsis or ARDS.  Following incubation, 
flow cytometry will be used to examine the effect of diet on altering neutrophil 
lifespan in both an inactive and LPS activated cell state.  Gas 
chromatography analysis of liver tissue will be utilized to provide information 
on the incorporation of EPA and SDA from dietary sources into membrane 
phospholipids.    
The significant features of this study are many fold; first, feeding purified 
EPA ethyl ester will allow us to confirm and examine the incorporation of EPA 
into membrane phospholipids.  Using gas chromatography we can examine 
whether EPA ethyl ester provided in the diet is directly incorporated into 
membrane phospholipids, and if it is enzymatically altered and stored as other 
n-3 fatty acids. This design will also allow us to confirm previous studies that 
indicate EPA content in membrane phospholipids is increased at the expense 
of AA.  Second, simultaneous feeding of diets containing purified SDA ethyl 
ester will allow us to examine the potential of dietary supplementation with 
SDA as an alternative to diets enriched with EPA for modifying membrane 
phospholipid fatty acids.   Third, pre-feeding animals diets containing EPA 
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and SDA also allows us to examine the effect of fatty acid incorporation and 
membrane pre-loading with respect to neutrophil lifespan and apoptosis.  Ex 
vivo treatment of neutrophils allows us to examine the effect diet may have on 
lifespan in both the inactive and endotoxin activated conditions in cells from 
individual animals.  This design utilizes both endotoxin treated and untreated 
cells from the same animal; thereby, allowing each animal to act as its own 
control, minimizing the potential for genetic variability on the effect of diet or 
endotoxin treatment.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
III. Objectives 
 
Objective 1:  To examine whether diets supplemented with SDA ethyl ester 
can be used as a precursor to increase EPA content in liver phospholipids 
and to determine the effectiveness of SDA in increasing tissue EPA and 
reducing tissue AA content in rat liver. 
 
Objective 2:  To evaluate the effect of dietary EPA and SDA on the regulation 
of basal and endotoxin-induced neutrophil survival using glycogen-elicited 
peritoneal neutrophils from the rat. 
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I.  Essential Fatty Acids and Eicosanoid Synthesis 
 
Essential Fatty Acids: 
In 1929 Burr and Burr discovered that the exclusion of certain fatty acids from the 
diets of laboratory rats would produce a disease state.  Animals developed scaly 
skin, swollen and scaly tails, and hair loss from the face, tail, and throat[1].  
These fatty acids were later termed “essential” because higher mammals lack the 
enzymatic pathways responsible for their synthesis de novo, and they must be 
obtained from the diet[2].  Essential fatty acids are polyunsaturated fatty acids 
(PUFAs), meaning that they are 18 carbons or more in length and have 
numerous double bond positions throughout their carbon backbone.  The 
positioning of the first double bond proximate to the methyl end of the fatty acid is 
used as a reference to classify essential PUFAs as members of either the 
omega-6 (n-6) or omega-3 (n-3) family of fatty acids[3].  The essential nature of 
these PUFAs is due to the lack of enzymes responsible for desaturation past the 
ninth carbon of the fatty acid chain from the carboxylic end of the molecule.  
Further, it has been shown that fatty acids from these families are not 
interchangeable[4].  
 The parent fatty acids of the n-6 and the n-3 families of fatty acids are 
linoleic (LA; 18:2n-6) and α−linolenic (ALA; 18:3n-3) acids, respectively. In the 
strictest sense of the term, only the parent compounds of the n-6 and n-3 are 
truly essential, as an enzyme system exists to elongate and desaturate the 18 
carbon PUFAs to form the other members of the essential fatty acid family[5].  
Although, as previously mentioned these fatty acid families are not 
interchangeable, they are metabolized by the same enzymatic elongation and 
desaturation pathways[3] (Figure 2.1).  LA is desaturated and elongated to form 
arachidonic acid (AA; 20:4n-6), which is considered to be the bioactive n-6 fatty 
acid for the production of inflammatory compounds[6].  Along the same lines ALA 
can be converted to stearidonic acid (SDA; 18:4n-3) and then to  
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 Figure 2.1 Pathways of Fatty Acid Synthesis. 
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eicosapentaenoic acid (EPA; 20:5n-3), which is the n-3 fatty acid counterpart to 
AA, and has been shown to attenuate the formation of proinflammatory products  
attributed to AA metabolism[7].  For this discussion we will focus on AA, SDA, 
and EPA.  The main dietary source of AA is from consumption of animal 
products, although a small amount is synthesized by metabolism of LA from plant 
sources[8].  The beneficial effects of fish oil have been mainly attributed to the 
long chain PUFAs EPA and DHA.  Typically, DHA nor EPA are not produced in 
terrestrial organisms, but found primarily in marine sources, such as cold water 
fish and fish oil[9;10].  SDA has been found in low abundance in certain seed 
oils, such as from Echium plantaginium, and recently has been produced in 
genetically modified canola plants[10;11].  Lipid derived eicosanoid products of 
AA metabolism have been ascribed a vital role in the development of 
inflammation, and have been implicated in the pathogenesis of sepsis, systemic 
inflammatory response syndrome, acute lung injury and acute respiratory 
distress syndrome[8;12]. 
 Because of safety concerns associated with fish consumption, cost, and a 
limit on natural fish stocks the inclusion of fish into the western diet on a large 
scale is problematic and impractical[13].  Thus, there has been an urgent need 
for the location of alternative sources by which to provide n-3 PUFAs to the diet.  
Initially, the potential of ALA provided by diet to increase tissue levels of EPA and 
DHA was examined.  These studies found that this reaction is too inefficient for 
dietary ALA to significantly alter the levels of n-3 fatty acids found in tissue 
membrane phospholipids[10].  The conversion of ALA to EPA is a three step 
enzymatic process, in which ALA is first desaturated by the ∆6 desaturase 
enzyme to SDA and then elongated by 2 carbons to form EPA.  The ∆6 
desaturase enzyme has been shown to be the rate limiting step in the conversion 
of ALA to EPA[14].  Stearidonic acid is the product of ∆6 desaturase activity on 
ALA, and has gained interest as a precursor fatty acid for increasing n-3 PUFA 
content in tissue phospholipids, as it bypasses the rate limiting step in fatty acid 
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conversion to EPA and has been shown in some models to be more efficient at 
increasing tissue EPA as compared with ALA provided by diet[15].    
 Eicosanoids are biologically active products of either enzymatic or non-
enzymatic oxidation of 20 carbon chain length PUFAs[6].  Synthesis of 
eicosanoid products begins with the cleavage of either AA or EPA from their 
storage position in the sn2 position of the cell membrane phospholipids.  This 
cleavage is carried out by cystolic phospholipase A2 (cPLA2), which is a member 
of a broad family of enzymes that are characterized by their ability to hydrolyze 
the center, sn2, position of substrate phospholipids[16].  Activation of cPLA2 is a 
calcium dependant process, and yields a free fatty acid that can then be ferried 
to the nuclear membrane of the cell for further metabolism by cyclooxygenase, 
lipoxygenase, or cytochrome p450.  For this discussion we will focus on the 
products of the lipoxygenase and cyclooxygenase enzyme pathways. 
 
Cyclooxygenase Activity: 
Prostaglandin endoperoxidase H synthases (PGHS; cyclooxygenase; COX) 
catalyze the committed step in the formation of prostanoid products from the 20 
carbon fatty acids.    There are two isoforms of COX enzymes, COX1 and COX2, 
both of which share approximately 60-65% sequence homology.  All of the amino 
acids deemed necessary for COX1 function are present in the COX2 
enzyme[17].  COX1 is a 576 amino acid length protein, while COX2 is a 587 
amino acid protein. COX1 is considered to be constitutively active, and is 
involved in the production of housekeeper molecules, while COX2 is an inducible 
enzyme and is mainly activated in response to inflammatory stimulus which 
results in an enhanced prostaglandin production[18;19].  COX2 possesses an 18 
amino acid sequence, inserted 6 residues in from the C-terminus that is not 
present on the COX1 enzyme[20].  Both isoforms of COX enzymes are located 
on the luminal face of the endoplasmic reticulum, and on both the inner and outer 
faces of the nuclear envelope.  COX2 is more concentrated on the inner surface 
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of the nuclear envelope, possibly to facilitate the role of its products as nuclear 
regulators.     
COX1 and COX2 utilize a two-step conversion process to metabolize AA 
to prostaglandin H2 (PGH2).  This conversion is carried out by two discreet active 
sites on the enzyme.  First, AA is combined with two molecules of oxygen in a 
bis-oxygenase reaction to form prostaglandin G2 (PGG2) in an enzymatic pocket 
on the hydrophilic surface of the enzyme.  PGG2 is then transported to a second 
pocket in the hydrophobic core of the COX1 enzyme where it is reduced to form 
PGH2 through a peroxidase reaction that removes two electrons from PGG2[17].   
PGH2 from COX1 is then released into the cytoplasm of cells to be converted to 
an active prostaglandin by other enzymes.  Whereas PGH2 formed by the COX2 
enzyme most likely is transported to the nucleus[17].   
Metabolism of AA by COX1 or COX2 results in the formation of the 2- 
series prostaglandins, where the subscript 2 denotes the number of double 
bonds in the molecule.  Both COX1 and COX2 are capable of metabolizing EPA 
to prostaglandin products, although at a greatly reduced rate[21].  The additional 
double bond found in EPA as compared with AA results in the formation of 
prostaglandin products containing 3 double bonds along the carbon backbone of 
the molecule.  These products are denoted by the subscript 3 (i.e., PGH3), and 
are referred to as the 3-series prostaglandins.   
Once released into the cell cytoplasm, the PGH products of COX activity 
can be metabolized by a number of enzymes to form prostaglandin products 
which are actively involved in cell signaling.  These include PGE2, PGD2, PGF2α, 
PGI2, and thromboxanes.  PGD2 can be transformed by two steps of dehydration 
and one step of double bond migration to form ∆12-PGJ2 and 15-deoxy-∆12,14-
PGJ2, which have been shown to induce apoptosis in neutrophils[22]. The 
reactions involved in transforming AA to cell signaling products are carried out by 
discreet heterogenous enzymes and non-enzymatic reactions.  The 
prostaglandin products of AA metabolism have been linked with the pain, 
redness, and swelling associated with inflammation[19].  PGE2 induces fever, 
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increases vascular permeability, vasodilation, as well as pain and edema 
enhancement[23].  However, on the cellular level PGE2 has also been shown to 
exhibit anti-inflammatory actions such as reducing lymphocyte proliferation, and 
suppressing the production of pro-inflammatory cytokines such as TNF-α, IL-1, 
and IL-6[18].  PGI2, or prostacyclin, exerts potent anti-thrombic and vasodilatory 
effects through interaction with vascular smooth muscle tissue and platelets[24].  
Thromboxane A2 (TXA2) is produced by activated platelets and has strong 
thrombogenic, vasoconstrictive, and bronchoconstrictive properties[25]. 
As mentioned above, EPA can be metabolized by the COX enzymes, 
although at a reduced rate as compared with AA to form the 3-series 
prostaglandins.  During prostaglandin formation there is further competition 
(aside from competing for position in the cell membrane) between the two 
classes of PUFA for COX activity which results in a decrease in the formation of 
AA derived COX products.  Many of the products of EPA metabolism exhibit a 
reduced biological activity[26].  For example thromboxane A3, a product of EPA 
metabolism, is a weak vasoconstrictor and weak platelet aggregator as 
compared with TXA2 derived from AA[23].  The biological activities of PGE3 are 
also muted as compared with PGE2[27].  Besides the decreased biological 
activity of PGE3, EPA has also been demonstrated to decrease the production of 
PGE2[28]. There are exceptions, however, such as the case of  the EPA 
prostacyclin product, PGI3, which is as biologically active as PGI2 as a 
vasodilator and platelet aggregator[23]. 
Prostaglandins exhibit their effects, with few exceptions, via a family of 
prostaglandin receptors.  Each of the receptors has a high binding affinity for a 
specific prostaglandin, although there can be considerable cross reactivity 
among the receptors and ligands.  The prostaglandin receptors are seven 
transmembrane domain receptors, belonging to the heterodimeric G-protein- 
coupled, rhodopsin-type superfamily[29].  The nomenclature of receptors is 
based on the ligand that they bind.  For example, DP binds to PGD, TP binds to 
thromboxanes, IP binds to PGI, etc..  Within this superfamily of receptors the 
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branch dedicated to PGE binding is composed of four members (EP1, EP2, EP3, 
EP4), constituting a complete receptor sub-family[25].  Each prostaglandin 
receptor can be classified in one of three categories, based on the G-protein 
homodimer activated, and the cell response.  These categories are the relaxant 
receptors, contractile receptors, and the adenylate cyclase inhibitors.  The 
relaxant receptors consist of IP, EP2, EP4, and DP.  Activation of these receptors 
stimulate cAMP production through adenylate cyclase activation[29-31].  The 
contractile receptors are TP, EP1, and FP and are associated with increasing 
intracellular calcium levels[29;32].  EP3 is the sole member of the adenylate 
cyclase inhibitor family[29].  Exceptions to the prostaglandin ligand-receptor motif 
are the PGJ products of PGD metabolism.  These prostaglandins have no 
specific cell surface receptors, instead are actively transported across the cell 
membrane[33].  Once inside the cell they can interact with proteins directly via a 
cross conjugated dienone unit that can react with thiol nucleophiles, thereby 
altering protein function[22].  
 
Lipoxygenase Activity: 
The lipoxygenase enzymes are a class of non-heme iron containing enzymes 
that catalyze the incorporation of molecular oxygen into PUFAs[25].  This 
reaction is positionally selective, which is reflected by lipoxygenase 
nomenclature, as the enzymes are named after the carbon atom that they 
preferentially attack.  Based on this system of classification the lipoxygenase 
enzymes are divided into three categories; the 5-, 12-, and 15-, lipoxygenases, 
respectively[25].   
12-lipoxygenase (12-LO) was the first lipoxygenase enzyme to be 
discovered in the mammalian system, and has been found in the cytosolic 
fraction of a number of cell types. There are reports that state that 12-LO is 
translocated to the cell membrane in a calcium dependent mechanism, and that 
this translocation deactivates the enzyme[34-36].  12-LO is primarily responsible 
for the synthesis of 12-hydroperoxyeicostetraenoic acid (12(S)-HPETE) from AA, 
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which is the parent compound of the hepoxilins and trioxilin[34].  Hepoxilins are 
monohydroxy-epoxy derivatives of PUFAs and consists of two known derivatives, 
hepoxilin-A3 and –B3.  Hepoxilins can be hydrolyzed to form another metabolite 
group called trioxilins, which also has two derivatives, (trioxilin –A3 and B3) 
depending on the precursor molecule[34]. 12-LO can also metabolize EPA to 12-
hydroperoxyeicospentaenoic acid (12(S)-HPEPE).  Although the biological 
activities of the 12-LO PUFA metabolites are much less well defined than those 
of the prostaglandins or the biologically active leukotriene products of 5-
lipoxygenase activity, they have been shown to be involved in a number of 
processes, including the increase of intracellular calcium in neutrophils by 
hepoxilins A3[34;37].  More work is needed to determine the effects of 12-LO 
products during pathological conditions. 
15-lipoxygenase (15-LO) is another cytosolic protein member of the 
lipoxygenase family, which catalyzes the oxygenation of AA to 15-
hydroperoxyeicosatetraenoic acid (15 (S)-HPETE), and similarly transforms EPA 
to 15-hydroperoxyeicosapentaenoic acid (15 (S)-HPEPE)[25;38].  15-LO was first 
discovered in rabbit reticulocytes, and later two separate isoforms were identified 
in humans[39].  These isoforms are 15-LOa and 15-LOb, and are classified 
based on tissue distribution and substrate specificity.  15-LOa was the same 
protein that was first purified from rabbit reticulocytes, and is widely distributed in 
human eosinophils, bronchial epithelial cells, peripheral blood leukocytes, liver, 
kidney, spleen, thymus, testis, skeletal muscle, heart, and brain.  In contrast, 
15LOb has only been isolated in the prostate, skin, lung, and cornea[39].  15-LO 
is also an active enzyme for shorter chain 18 carbon fatty acids, such as LA or 
ALA.  A second feature unique to15-LO is that it can also oxygenate metabolites 
that are esterified to phospholipids, independently of phospholipase activity[25].  
It has been shown that each 15-LO isoform preferentially utilizes different 
substrates. 15-LOa preferentially metabolizes LA to 13(s)-
hydroperoxyoctadecadienoic acid (13(S)-HODE), and metabolizes AA to 15(S)-
HETE.  In contrast, 15-LOb converts AA to 15(S)-HETE, but is a poor enzyme for 
 
 27
LA[39].  Products of 15-LO metabolism have been shown to possess various 
biological properties in a number of cell types.  15(S)-HETE has been shown to 
modulate pain response in rat skin, alters the growth of rat liver epithelial cells, 
regulates the secretion of prolactin in fibroblasts, induce a hypersensitivity to the 
β-adrenergic response in rat cardiomyocytes, and in erythroleukemia cells 15-
HETE has been shown to regulate protein phosphorylation and cell 
proliferation[40].  13-HODE has been linked with inducing histamine 
hypersensitivity in guinea pig airways, and modulating the EGF signaling tyrosine 
phosphorylation in fibroblast cultures[25;40].  There have been some studies that 
imply a particular importance for 15-LO in the lung, at least in epithelial cells.  
Several studies have demonstrated that tracheal and bronchial epithelial cells 
produce 15-LO products, and that the removal of the epithelial layer results in a 
reduction of 15-LO activity[38;41;42].  In other studies15-HETE has been shown 
to induce mucus and chloride secretion in human lung epithelium, and mucus 
secretion and inflammation in canine airway epithelium[40].  The involvement of 
15-LO in the inflammatory response has been illustrated in several studies in 
which it has been shown to reduce 5-lipoxygenase activity, reduce leukotriene 
mediated chemotaxis, and reduce superoxide anion generation in 
neutrophils[39].  In one of the most recent studies, the 15-LO product, 15-HETE 
was shown to have a regulatory effect on the LPS-induced production of tumor 
necrosis factor-α in human monocytic cell lines.  15-HETE exhibited this effect by 
degrading TNF-α mRNA[43].   
Perhaps the most well studied of the lipoxygenase enzymes is 5-
lipoxygenase (5-LO).  This enzyme pathway is responsible for the production of 
the leukotrienes, which have been shown to have a wide range of effects on 
inflammation and innate immunity[44].  Intracellularly, 5-LO is located in the 
cytosolic fraction of resting leukocytes and upon activation associates with the 
nuclear envelope[45].  5-LO requires an interaction with both phospholipase A2 
and 5-LO activating protein (FLAP)[46].  Following cleavage of AA or EPA from 
the cell membrane by PLA2, FLAP along with PLA2 and AA translocate to the 
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nuclear envelope to the site of 5-LO[45].  The translocation of all these 
participants of 5-LO enzyme activity are calcium dependant, based on studies 
using the calcium ionophore, A23187[47-49].  Following nuclear assembly of the 
5-LO complex the enzyme can catalyze the synthesis of the leukotrienes from AA 
or EPA.  Metabolism of AA results in the formation of the 4-series leukotrienes, 
while EPA metabolism results in the formation of the 5-series leukotrienes[50].  
5-LO first converts AA to 5-(S)-hydroperoxyeicosatetraenoic acid (5-HPETE), 
and then converts 5-HPETE to leukotriene A4, which is the parent compound for 
leukotriene synthesis[51].  LTA4 is an unstable epoxide that can either be 
enzymatically conjugated with reduced glutathione to form leukotriene C4 (LTC4), 
or hydrolyzed to leukotriene B4 by LTA4 hydrolase[52].  LTC4 is the parent 
compound of the cysteinyl leukotrienes, which were originally described as the 
slow reacting substances of anaphylaxis.  LTC4 can be metabolized to leuko-
triene D4 (LTD4) by elimination of glutamic acid by γ-glutamyl transpeptidase.  
LTD4 can be hydrolyzed by a dipeptidase to leukotriene E4, removing the 
remaining peptide bond, forming LTE4[53].   
The cysteinyl leukotrienes are produced mainly by activated eosinophils, 
basophils, mast cells, and macrophages.  They were first identified by their 
smooth muscle contracting properties, and were associated with asthma and the 
allergic response[54].  Although there have been some recent papers that 
implicate the cysteinyl leukotrienes with the release of pro-inflammatory 
cytokines, an increase in microvascular permeability, and the induction of 
pulmonary fibrosis[55]. 
LTB4 is a leukotriene of major importance in regards to immune function 
and the inflammatory response.  Structurally LTB4 is similar to the cysteinyl 
leukotrienes, having a 20-carbon backbone, and multiple double bonds, although 
lacking the peptide side chain, but possessing an additional hydroxyl group at C-
12[56].  LTB4 is produced mainly by immune cells such as alveolar macrophages, 
and acts as a potent chemoattractant and stimulator of neutrophils to sites of 
infection and inflammation[44].  LTB4 has been shown to promote neutrophil 
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chemotaxis, and to up-regulate the interaction between activated neutrophils and 
vascular endothelial cells[19].  LTB4 is a stimulator of lysosomal enzyme and 
superoxide anion release in neutrophils.  LTB4 also increases the generation of 
the chemotactic agent interleukin-8 by neutrophils[56].  LTB4 has also been 
shown to mediate survival in neutrophils by decreasing apoptosis[19].  There 
have also been reports that LTB4-mediated cell survival is associated with the 
survival pathway observed when neutrophils are exposed to bacterial endotoxin, 
although this is debated[57;58]. LTB4 is an important mediator for the immune 
system, especially in the lung, where alveolar macrophages have been shown to 
exhibit an enhanced release of LTB4 as compared with other monocytes, 
indicating the role of LTB4 as an early response mediator of innate immunity[41].  
As previously mentioned, lipoxygenase enzymes can form EPA derived 5-series 
leukotriene products.  This is the case with LTB5, which is structurally related to 
LTB4, but is less biologically active[59].   
Like the products of the cyclooxygenase pathway, both LTB4 and the 
cysteinyl leukotrienes exhibit their effects through interactions with members of 
the G-protein-seven-transmembrane receptor family.  LTB ligands interact with 
two surface receptors; BLT1 and BLT2.  These receptors are present in high 
numbers on inflammatory cells and vascular endothelial cells. Coupling of LTB to 
either receptor induces an increase in intracellular calcium levels as well as 
chemotactic responses in neutrophils[60].  The cysteinyl leukotrienes interact 
with two receptors as well.  These are CysLT1 and CysLT2 receptors.  These 
receptors have been found in bronchial tissue, and expressed on CD45+ 
leukocytes, macrophages, mast cells, neutrophils, and eosinophils in 
humans[55]. 
Another class of lipoxygenase products is the lipoxin family.  The name 
lipoxin is an acronym for lipoxygenase interaction products.  These eicosanoids 
are products of multiple lipoxygenase enzyme reactions that are carried out in 
cell-to-cell interactions[25].   The lipoxins were first identified by Serhan et al[61] 
from purified fractions of leukocyte suspensions that were coincubated with 15-
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HETE and calcium ionophore A23187. Lipoxygenase formation occurs by one of 
three pathways (two of which occur naturally and one of which involves the non-
steroidal anti-inflammatory drug, aspirin) depending on the cells involved in 
interactions at the time of formation[62].  The earliest pathway to be described 
was for the formation of lipoxin A4 (LXA4) [63;64].  This formation involves the 
interaction between neutrophils and platelets.  5-LO activity in the neutrophil 
produces LTA4, which is released from the neutrophil and taken up by the 
platelets.  12-LO activity inside of the platelets then transforms LTA4 to LXA4. A 
second pathway involves the interaction between 15(S)-HPETE or 15(S)-HETE 
formed by vascular endothelial cells.  During activation neutrophils begin to roll 
along vascular endothelial cells in response to chemotactic stimuli, during this 
interaction they can pick up the 15-LO products from the endothelial cells.  These 
products are subjected to metabolism by 5-LO in the neutrophil and forms an 
unstable intermediate, 5,6-epoxytetraene (5,6-ETE).  5,6-ETE is rapidly 
converted by epoxide hydrolases to three products, LXA4, LXB4, or 7-cis,11-
trans-lipoxinA4[25].  The final pathway for lipoxin formation involves the 
acetlyation of COX-2 by aspirin.  This shifts the activity of the COX-2 enzyme in 
monocytes to one that mimics a lipoxygenase enzyme, forming the product 
15(R)-HETE.  15(R)-HETE is structurally similar to 15(S)-HETE formed by 15-LO 
with the exception that the 15-C in the chain has its alcohol group in the R 
conformation.  Once released, 15(R)-HETE can be taken up by neutrophils and 
metabolized by 5-LO, forming 15-epiLXA4, or 15-epiLXB4[65].   
The pharmacological activities of the lipoxins are involved heavily in the 
resolution of inflammation.  They have been shown to inhibit neutrophil and 
eosinophils trafficking by reducing sensitivity to LTB4 and PAF, as well as to 
stimulate the macrophage mediated clearance of apoptotic neutrophils[66].  
Lipoxins exert their influence in two ways.  First there is a lipoxin-specific 
recognition site that has been localized on human neutrophils.  This is thought to 
be a member of the G-protein-coupled receptor superfamily, although the 
downstream signaling has yet to be elucidated.  Also, lipoxins are competitive 
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inhibitors of cysteinyl leukotriene receptors[62].  Substitution of AA with EPA 
leads to the formation of the 5-series lipoxins, which have been shown to be 
equally as active as signaling molecules as their AA derived counterparts[67]. 
 
Benefits of EPA and SDA: 
As mentioned before, the addition of SDA to the diet may have beneficial effects 
on inflammatory mediator production because of its potential to be elongated to 
EPA[14;68].  SDA has also been shown to possess inhibitory effects on the 
oxygenation of AA to eicosanoid products[69].  This effect was later 
demonstrated to be due to an inhibition of ∆5-desaturase activity[70].  The 
inclusion of EPA into diet or nutritional formulas has been shown to have potent 
anti-inflammatory effects in vivo[71-73].  Ex vivo, dietary EPA has been shown to 
reduce the synthesis of interleukin-1 and tumor necrosis factor-α by activated 
monocytes[74].  EPA has been shown to reduce the formation of PGD2 by 
inhibiting COX-2[75].  Besides inhibitory effects, EPA can be used as a substitute 
for AA in the formation of eicosanoids[8].  This substitution leads to the formation 
of products that are much less bioactive than their AA derived cousins.  One 
example of this is LTB5 which is much less active than LTB4[76].     
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II. Apoptosis 
 
Mechanisms of Apoptosis: 
Apoptosis is an active process by which cells undergo a controlled breakdown of 
systems and molecules, leading to programmed death.  Apoptosis was first 
observed in the late 19th century by C. Vogt during morphological examinations 
of amphibian cells.  This process was lost and rediscovered over the years in a 
variety of cell types.  The term apoptosis was coined in a paper by Kerr et al in 
order to describe non-necrotic cell death[77].   The apoptotic process begins in 
response to a stimulus, which triggers an energy requiring pathway leading to 
destruction of the cell by a characteristic set of reactions[78].  Necrosis is a 
passive process, typically in response to some insult to the cell leading to a loss 
of membrane integrity.  The fate of the necrotic cell is fluid influx, swelling, and 
eventually rupture, emptying the contents of the cell into the environment[77].  
The apoptotic pathway, on the other hand, leads to the inactivation and death of 
the cell without loss of the external membrane.  As previously mentioned, 
signaling molecules that are expressed on the cell membrane during the 
apoptotic process target these cells for removal by phagocytic cells before the 
loss of membrane integrity can occur.  Another important difference between 
apoptosis and necrosis is mitochondrial involvement.  During apoptosis several 
studies have shown that the mitochondria exhibit a loss in the mitochondrial 
membrane potential (∆Ψm) which coincides with the appearance of the 
permeability transition pore (PT).  This loss of mitochondrial membrane potential 
allows small pro-apoptotic proteins to leak into the cytosol, which amplifies and 
perpetuates the apoptotic signal[79].  The timing of mitochondrial participation 
has been used to elucidate the existence of two separate signaling pathways for 
apoptosis, which will be discussed further.  Although apoptosis is an important 
process for the normal physiological functioning in numerous systems, this 
discussion will focus on the pathways and factors associated with apoptosis in 
the neutrophil and the inflammatory process. 
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    Regardless of cell type, apoptosis is an ordered process which consists 
of 3 phases; initiation, execution, and termination.  Initiation can occur by a 
number of intrinsic and extrinsic factors.  Several examples of apoptotic inductors 
are growth factor withdrawal, ultraviolet or gamma radiation exposure, 
chemotherapeutics, or activation of membrane expressed cell death 
receptors[77].  Initiation by activation of cell death receptors is mediated through 
members of the tumor necrosis factor/ nerve growth factor (TNF/NGF) 
superfamily of receptors.  These receptors all share a cysteine-rich extracellular 
domain, and a signal transducing intracellular death domain (DD).  To date there 
have been six cell death receptors identified; TNFR1 (CD120a), CD95 (APO-1, 
Fas-1), DR3 (APO-3, LARD, Tramp, WSL-1), TRAIL R-1 (APO-2, DR-4), TRAIL 
R-2 ( DR-5, KILLER, TRICK-2), and DR-6.  Of these six, CD95 has been most 
well characterized.  In the CD95 model of apoptotic induction, activation of the 
CD95 receptor by CD95 ligand (CD95l) leads to oligomerization of TNF/NGF 
receptors, forming an apoptotic signaling complex.  Ligation and oligomerization 
of these receptors induces recruitment of the intracellular adaptor protein, Fas-
associated death domain (FADD), to the cytoplasmic portion of the receptors.  
Association of FADD with the DD of the receptor complex sequesters molecules 
of pro-caspase 8 to the site, which interacts with other components to form the 
death induced signaling complex (DISC)[77;80;81].  Pro-caspase 8 is a member 
of an important family of proteases that are responsible for the execution phase 
of apoptosis; namely, the caspases.  Caspases are a family of intracellular 
cysteine proteases with conserved sequence sites for binding and catalysis.  
Caspases cleave their substrates following accessible aspartic acid residues, 
which is where their name is derived (cysteinyl aspartate specific proteases).  
Cleavage of substrates by caspases leads to a cascade of signals that result in 
controlled deconstruction of proteins and DNA, making these proteases vital 
initiators and effectors of programmed cell death[80;82].   
 In order to control caspase activity, the molecules are initially produced as 
inactivated zymogens, composed of three domains: an N-terminal pro-domain, a 
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p20, and a p10 domain.  The active moiety is a heterodimer of the p20/p10 
domains, formed by the cleavage of the pro-domain.  The sites of cleavage 
required for caspase activation are all located following aspartate residues, 
making them candidate sites for autolytic cleavage.  Aggregation of pro-caspase 
8 molecules at the site of DISC formation increases their concentration 
sufficiently to allow autolytic activation to occur[83].   The proteolytic activation of 
caspase-8 begins a downstream cleavage of substrates, ultimately ending in 
apoptosis.  The caspase cascade depends on three vital caspase family 
members; caspases-3, -6, and -7, which are responsible for cleavage of specific 
death substrates.   These death substrates include various DNA repair 
molecules, ribonucleoproteins, signaling molecules, and structural proteins[77].  
In the simplest model of caspase-mediated apoptosis, caspase-8 can be viewed 
as an initiator caspase, activated at the DISC, leading to activation of executioner 
caspases -3, and -7 which in turn activates caspase -6.  This model is termed the 
“induced proximity model” of apoptosis[84].  In this model cleavage of caspase -3 
occurs prior to loss of the mitochondrial membrane potential, indicating a lack of 
dependence on the mitochondria[77].   
 In a second form of receptor-mediated apoptosis, the role of the 
mitochondria is crucial to the apoptotic signal transduction cascade that occurs 
between caspase-8 and caspase-3[85].   This form of apoptosis is described in 
cell types with low levels of caspase-8 association with DISC.  In this model the 
mitochondria act as signal amplifiers by releasing pro-apoptotic factors into the 
cell[86].  Mitochondrial dependent apoptosis involves interactions of several 
apoptotic signal regulating proteins, members of the BCL-2 protein family.  These 
proteins share four BCL sequence homology regions (BH 1-4) and have either 
pro or anti-apoptotic effects.  The BCL-2 family of proteins can be broken down 
into three archetypes.  Type 1 BCL-2 family members contain the BH-4 domain 
and are anti-apoptotic.  While the Type 2 and 3 BCL-2 family members lack this 
BH region and are pro-apoptotic[81].  The anti-apoptotic BCL-2 family members 
include BCL-2, BCL-XL, MCL-1, BCL-W, A1, and BOO.  The pro-apoptotic BCL-2 
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family members consist of two sub-types: Type 2 BCL-2 proteins contain BH 
regions 1-3, while type 3 BCL-2 proteins contain the BH-3 homology region only.  
The BH-3 region proteins include BAD, BID, BIM, BMF, BIK, BLK, HRK, NOXA, 
PUMA, NIX, and BNIP3.  While the BH-4 family members have been shown to 
have other roles besides apoptosis inhibition, the BH-3 only proteins have been 
identified as exclusive cell death promoters[80].  Although the mechanisms are 
still being determined, members of the BCL-2 family are thought to interact with 
the mitochondrial membrane by formation of pores; the pro-apoptotic BH-3 
members promote pore formation, while the BH-4 domain containing family 
members inhibit pore formation.    The presence of these pores allows leakage of 
several compounds into the cytosol of the cell, including cytochrome-c, which is a 
key component in formation of a holoenzyme complex called the 
apoptososme[77].  Dimerization of pro- and anti-apoptotic BCL-2 proteins results 
in formation of heterodimeric neutral molecules[81].  This model emphasizes the 
importance of a balance between pro- and anti-apoptotic family members, as 
shift towards the apoptotic proteins would induce a change in mitochondrial 
membrane potential, allowing cytochrome-c leakage to occur.  Regardless of 
mechanism, the role of the BCL-2 proteins can be simplified to the regulation of 
mitochondrial components, particularly cytochrome-c, into the cytosol.   
In mitochondrial-dependant apoptosis, signal transduction from caspase-8 
to caspase-3 requires activation of procaspase-9.  As previously mentioned, 
activation of procaspase-9 requires formation of the apoptosome[81].  The 
apoptosome is a wheel like protein heptamer, made up of seven molecules of 
cytosolic protein, Apaf-1, and mitochondrial cytochrome c[87].  Apaf-1 contains a 
long C-terminal extension with 13 repeats of a WD40 motif.  Apaf-1 also contains 
an amino-terminal caspase recruitment domain and nucleotide binding domain.  
Under normal circumstances Apaf-1 adapts a compressed conformation, which 
prevents oligomerization with other proteins.  Cytochrome c released from the 
mitochondria binds to the WD40 motif, inducing the protein to adapt an open 
conformation.  Following this unfolding process, Apaf-1 proteins can heptamerize 
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in an ATP dependent reaction to form a “seven spoke wheel” holoenzyme with 
the amino-terminal caspase recruitment domain facing the “hub”.   This allows 
the collection of procaspase-9 enzymes to the hub region of the enzyme.  
Dimerization of procaspase-9 leads to the activation of a single monomer of the 
subunit[87;88].  The completed apoptosome then activates caspase-3, which in 
turn activates other executioner caspases, and induces apoptosis in the same 
manner as the induced proximity model. 
 
Morphological Changes of Apoptosis:  
Morphological characteristics were first described at great lengths in a 1972 
paper by Kerr, Wyllie, and Currie following extensive electron and light 
microscopic observations[89].  The hallmark morphological characteristics occur 
during the termination phase of apoptosis, following initiation and activation of 
signaling molecules.   These changes are nuclear condensation, cell shrinkage, 
formation of apoptotic bodies, and finally phagocytosis by other cells[90].   
 Morphologically, the onset of apoptosis begins cell shrinkage and 
membrane blebbing.  Blebbing is thought to occur through proteolytic cleavage of 
structural components of the cell and nuclear membrane (cell death substrates), 
such as actin and fodrin cleavage by caspase-3 activated calpain[91].   While 
cellular shrinkage is a result of net loss of water from the cell to the extracellular 
environment from fusion of the golgi apparatus and endoplasmic reticulum with 
the cell membrane, and later the formation of apoptotic bodies[90].  Another very 
important change in the cell membrane is expression of phosphatidylserine on 
the outer membrane leaflet.  Phosphatidylserine (PS) is a protein that is actively 
confined to the inner leaflet of the cell membrane during normal circumstances 
by the enzyme, aminophospholipid translocase.  Relocation of PS to the outer 
leaflet of the cell membrane is brought about during the caspase-mediated 
cleavage of fodrin, which disrupts cell membrane symmetry and allows the PS 
molecule to “flip” to the outer cell membrane[92].  Expression of PS is vital for 
recognition and removal of apoptotic cells by macrophages[93]. 
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 Simultaneous to cellular shrinkage and membrane blebbing is a marked 
nuclear chromatin condensation.  This chromatin condensation results in 
formation of compact, crescent shaped masses about the nuclear envelope.  The 
nucleolus of the cell also undergoes shrinkage and chromatin aggregation. 
Eventually the nucleus itself begins to condense and break apart.  Nuclear 
changes, like those observed in the cytosol, are a result of protease activity. 
Chromatin condensation may be a result of the cleavage of lamin-B1, which is 
responsible for connecting chromatin to the nuclear matrix. Loss of nuclear 
structural integrity is also the result of caspase-mediated lamin-A 
degradation[90;91].   Activated caspases are also responsible for DNA cleavage 
into 180-200bp double stranded fragments.  This cleavage is mediated by DNA 
fragment factor (DFF40) and caspase-activated DNase (CAD).  Both of these 
molecules are constitutively present in an inactive form.  Cleavage of their 
inhibitor domains by caspase-3 activates their DNase properties[90].  
In later stages of apoptosis, cell membranes form elongated extensions.  
These extensions eventually break off and the plasma membrane seals to form a 
separate membrane around the detached solid cellular material.  These products 
of budding are termed apoptotic bodies.  Apoptotic bodies contain well 
preserved, albeit crowded, cellular structures and organelles.  These apoptotic 
bodies are usually quickly phagocytized by nearby macrophages; however, if 
allowed to remain they will degrade in a process that resembles necrosis, which 
has been termed secondary necrosis[90;94]. 
 
Apoptosis Versus Necrosis: 
As previously mentioned, apoptotic cells that are not engulfed by phagocytic cells 
eventually degrade into a necrotic-like state.  Necrosis is a modality of cell death 
that is typically induced by some insult.  The process of necrosis is a passive 
one.  Morphologic changes to the cell involve a loss in plasma membrane 
integrity, which allows influx of water and electrolytes.  This fluid influx causes a 
rapid swelling of the cell leading to rupture of the cell membrane, and loss of cell 
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contents to the extracellular environment[90;95].  Necrosis also brings about an 
irregular chromatin clumping in the nucleus.  
 Apoptosis is an energy requiring, orderly process.  The process of 
apoptosis can be disrupted or altered by deletion or perturbation of pathway 
members[81].  Histologically, apoptosis occurs in individual cells, whereas 
necrotic cells often occur in clumps of tissue and are often thought of as being 
indicative of a pathological condition[95].  Also, apoptotic cells do not induce an 
inflammatory reaction, owing to the maintenance of membrane integrity until 
clearance, whereas necrotic cells are associated with a spillage of cellular 
components that induces an inflammatory reaction[94].   
 Perhaps the most striking contrast between apoptosis and necrosis is the 
lack of surface changes in the cell membrane.  The difference between apoptosis 
and necrosis membrane changes are best illustrated by the observation that 
necrotic cells are not engulfed by phagocytes and can induce an inflammatory 
response.  Lack of recognition by phagocytic cells implies that the basic changes 
in expressed proteins and signaling molecules that become expressed during 
caspase activation are not present on necrotic cells[96].   The differences in 
surface membrane expression has been exploited by researchers as a way to 
differentiate cells that died via the apoptotic route from those that died by 
necrosis; i.e., as with the use of TUNEL or annexin-V staining combined with flow 
cytometry[97;98].   
 
Role of Apoptosis in Inflammatory Cell Homeostasis: 
Apoptosis in neutrophils (PMNs) is an important process in maintenance of 
homeostasis.  In the non-disease condition approximately 1-2 x 1011 PMNs are 
produced in the bone marrow of human beings and released into circulation 
daily[99].  Clearance by apoptosis is vital in order to avoid an overabundance of 
these cells.  During infection numerous factors can not only sequester PMNs to 
the site of inflammation or infection, but also significantly decrease the rate of 
constitutive apoptosis.  The apoptotic process in PMNs is very similar to that 
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observed in other cell types.  It includes cytoplasmic condensation, aggregation 
and cleavage of nuclear chromatin, and formation of apoptotic bodies[100].   
Apoptotic events in PMNs also lead to recognition of these cells by phagocytes, 
such as macrophages, which dispose of the neutrophil before loss of membrane 
integrity leads to the accidental release of cytotoxic compounds[101].  Of equal 
importance is loss of receptor mediated functional properties of apoptotic PMNs.  
Apoptotic PMNs have been shown to exhibit decreases in cytokine production, 
chemotaxis, phagocytosis, oxidative burst capabilities, and degranulation[102]. 
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III. Bacterial Endotoxin 
 
Bacterial endotoxin is a lipopolysaccharide molecule (LPS) found in the cell wall 
of Gram negative bacteria.  LPS molecules are amphiphilic molecules consisting 
of a hydrophilic polysaccharide portion covalently linked to a hydrophobic lipid 
portion[103].  LPS is the predominant entity on the surface of bacterial cells; in 
fact one bacterial body contains approximately 3.5x106 LPS molecules, covering 
almost three-quarters of the bacterial surface[104].  When bacteria die and lyse, 
large quantities of LPS are released into the extracellular environment.  
Recognition of bacterial LPS by immune cells causes induction of the 
inflammatory response, and a physiological cascade that can lead to endotoxic 
shock and death[103]. 
 
Structure and Function of LPS Components:  
As mentioned above bacterial LPS consists of a lipid portion covalently bound to 
a polysaccharide portion.  The polysaccharide portion can be sub-divided into 
two regions; the O-specific chain and the core oligosaccharide.  The O-specific 
chain is a polymer of oligosaccharide units that can have as many as fifty 
repeats[105].  The structure of the O-specific chain is highly variable, even from a 
single bacterial strain, which allows LPS to exhibit a large amount of functional 
variability.  The core region of LPS is a hetero-oligosaccharide consisting of an 
inner and outer portion.  The outer portion of the core region is proximal to the O-
specific chain, while the inner portion is located adjacent to the lipid A portion of 
LPS[104].   Of the two core protein components, the inner portion of the core 
region is more highly conserved.  This is reflected by the finding that regardless 
of bacterial species, the inner core typically contains a 2-keto-3-deoxyoctonic 
acid (Kdo) and L-manno-D-mannoheptose (L,DHep) portion.  The outer portion of 
the LPS core region exhibits more variability in structure, as illustrated by the 
existence of at least 5 sub-types of outer core regions in E. coli[106].  Connected 
to the inner core region is the lipid A portion of the LPS molecule.  Lipid A is the 
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most highly conserved component of LPS.  Lipid A is an acetylated and 
phosphorylated disaccharide of glucosamine[107].  Lipid A is well known as the 
toxic and immunomodulating principle of bacterial LPS, as was demonstrated in 
studies where chemically synthesized lipid A, devoid of polysaccharide 
component, would induce biologic activities, both in vitro and in vivo that mimic 
those observed by bacterial LPS[105].   
 
Recognition of LPS by Host Cells: 
The biological activities of LPS in regards to eliciting an immune response from 
host cells is dependent on interaction between LPS, LPS binding protein (LBP), 
and the cell surface receptor, CD14[108].  The first step in recognition of bacterial 
LPS by immune cells is binding of LPS to LBP.  LBP is a 60-kD serum 
glycoprotein that contains a high affinity binding region for the lipid A region of 
LPS[109].   Synthesized in hepatocytes, LBP is present in serum at <0.5µg/ml 
under normal circumstances, but can rise to 50µg/ml within 24h of induction of an 
acute phase response[110].  LBP opsonizes both LPS bound particles as well as 
intact bacteria, and mediates attachment to phagocytic cells such as 
macrophages by forming a complex with the cell surface receptor CD14[108].  
There has also been evidence presented for a biphasic function of LBP.  Some 
recent studies have indicated that lower concentrations of LBP will intercalate 
with the cell membrane of monocytes, enhancing the effects of LPS. While, at 
higher concentrations, LBP will bind to LPS aggregates in the extracellular milieu 
and inhibit their stimulatory properties[111].  Once LBP has bound to LPS it can 
complex with CD14.  CD14 is expressed as either a glycosylphosphatidyl-
inostitol-linked membrane protein on macrophages, monocytes, and neutrophils 
or as a soluble protein that can act as an LPS receptor for CD14 negative 
cells[103].  It should be noted that LPS is capable of binding to CD14 without 
LBP, but the presence of LBP greatly enhances this process[112].  Structurally, 
CD14 lacks a transmembrane domain, which means that proper signal 
transduction requires participation of another protein, toll-like-receptor-4 (TLR-4).  
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This protein is a member of the toll-like receptor family and mediates the 
activation of nuclear-factor-κB pathway[113]. 
 Activation of immune cells leads to a number of cellular and physiological 
responses.  Macrophage activation by LPS induces production of 
proinflammatory mediators such as tumor necrosis factor-α, interleukin-1, and 
pro-inflammatory eicosanoids.  LPS induces a chemotactic response in 
neutrophils, as well as activates COX-2, and primes neutrophils for enhanced 
production of LTB4[114;115].  Activation of the TLR receptor pathways have been 
shown to induce or prime cytokine production, superoxide production, and L-
selectin shedding in human neutrophils[116].  Neutrophil exposure to LPS also 
induces a survival pathway through inhibition of constitutive neutrophil 
apoptosis[116].  Activation of the inflammatory response by LPS is linked with 
induction of numerous inflammatory diseases, such as endotoxemia or sepsis, 
the latter of which will be discussed in further detail [117;118]. 
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IV.  Systemic inflammatory Response Syndrome 
 
Introduction to SIRS: 
The clinical definition of sepsis is the systemic inflammatory response to 
documented infection[119].   It has since been recognized that other factors 
aside from bacterial infection can trigger an inflammatory response.  The term 
Systemic Inflammatory Response Syndrome (SIRS) was put forth by the 
American College of Chest Physicians and the Society of Critical Care Medicine 
at a consensus conference in 1992 to define the inflammatory response 
classically referred to as sepsis, independent of cause[120].  Clinically SIRS is 
diagnosed by the presence of more than one of the following symptoms: body 
temperature greater than 38ºC or less than 36º C, heart rate greater than 90 
beats per minute, a respiratory rate greater than 20 breaths per minute, or 
hyperventilation indicated by PaCO2 of less than 32mmHg.  Hematologically, 
there is an alteration of white blood cell count; either greater than 12,000 cu/mm 
or less than 4,000 cu/mm, and possibly accompanied by an increase (10%) of 
immature neutrophils[120].  Further criteria describe the severity of the 
inflammatory reaction based on the presence of additional symptoms associated 
with the progression of sepsis.  Severe sepsis is defined as organ dysfunction or 
sepsis-induced hypotension.  The most severe form of sepsis, septic shock, 
meets the previous criteria along with sepsis-induced hypotension that persists 
regardless of fluid resuscitation and accompanied by sepsis induced organ 
dysfunction.  Epidemiologic studies of sepsis indicate variable hospital and 
intensive care unit occurrence rates of 2-11% of all adult admissions, with a 
mortality rate of about 49%[121].   
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Etiology of Sepsis:  
The initial onset of sepsis occurs with a bacterial infection.  During their life cycle, 
bacteria shed numerous antigens, such as LPS, which are detectable by host 
immune cells. Sufficient numbers of bacteria may be able to release enough of 
these antigens to spill over into the host circulatory system.  Once in the 
bloodstream antigens are recognized by host immune cells.  Of particular 
importance for this step are macrophages[122].  Macrophages are specialized 
phagocytic white blood cells that are present in areas such as the sub-epithelium 
of the skin, alveolar tissue of the lung, or lining the blood sinusoids of the liver, 
spleen, and lymph nodes[119].   Macrophage activation leads to release of 
soluble factors, cytokines, that recruit and activate other cells; thus beginning the 
inflammatory cascade[122].  The proinflammatory cytokines also trigger release 
of several anti-inflammatory mediators that inhibit immune cell function and 
attempt to localize the inflammatory response[123]. This anti-inflammatory 
cascade provides a balance to the immune response to infection or injury.  
 
Inflammatory Mediators in SIRS/Sepsis: 
Macrophage activation by bacterial LPS initiates release of chemical mediators 
which are responsible for the pathology of sepsis.  This process begins with 
formation of a complex between LPS with LPS binding protein (LBP).  This 
complex is recognized and activates the CD14 complex found on the cell 
membrane.  TLR4 then transduces this signal through a signaling pathway that 
mediates degradation of the inhibitor molecule for nuclear factor (NF)κB. 
Activated NFκB is translocated to the nucleus of the cell, where it binds with DNA 
and promotes transcription of numerous genes responsible for  production of a 
host of pro-inflammatory cytokines including; tumor necrosis factor-α (TNFα), 
interleukin (IL) 1, granulocyte-colony stimulating factor (G-CSF), interferon-
γ (IFN-γ), IL-2, IL-6, and IL-12[122].   
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Tumor Necrosis Factor α:  TNFα is a 17-kDa, 157 amino acid polypeptide that is 
produced mainly by monocytes and macrophages. TNFα exists in both a 
membrane bound and soluble form.  Soluble TNFα is formed by cleavage of 
extracellular domain of the membrane bound molecule by metalloproteinase 
compounds, and is a 17-kDa molecule as compared with the membrane bound 
TNFα molecule which is 26-kDa[124].  Cleavage of soluble TNFα increases 
during infection or inflammation.  Leading to an increase of circulating TNFα, 
which has been shown to peak approximately one hour following insult[125]. 
TNFα initiates its effect by binding with two distinct surface receptors; a 55kDa 
receptor (TNFRI) and a 75kDa receptor (TNFRII). Originally it was believed that 
TNFRI was the primary receptor by which signal recognition of TNFα was 
received because of its higher affinity for the soluble form of TNFα.  However, it 
was later found that TNFRII plays an important role in sensing the presence of 
membrane bound TNFα in autocrine and paracrine interactions[126;127].  
Although TNFα binding to either of these receptors triggers activation of NFκB, 
other factors along the signal transduction pathways allow the molecule to exhibit 
different results.  For example, activation of TNFRI and the proceeding signal 
transduction pathway initiates apoptosis, while activation of the TNFRII and the 
ensuing signaling cascade induces an increase in cytokine production.  
Transcription and expression of these receptors is under genetic control, which 
allows different levels of expression.  These expression levels modulate the 
likelihood of interaction with ligands[128]. TNFα has a variety of activities in 
numerous tissue types. For example, NFκB activation in vascular endothelial 
cells by TNFα up regulates expression of adhesion molecules such as E-selectin, 
ICAM-1, and VCAM[119].  Increased expression of these molecules alters the 
surface of vascular endothelium and causes immune cells such as PMNs, 
macrophages, and CD4+ T cells to adhere and roll along the endothelium.  These 
molecules also alter the structure of vascular endothelium allowing diapedesis of 
inflammatory cells from circulation to sites of infection, as well as increasing 
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vascular permeability[122], all of which are important factors with sepsis 
associated disorders such as acute respiratory distress syndrome (ARDS).  
TNFα injection induces the production and release of other proinflammatory 
cytokines such as IL-1β, IL-6, IL-8, and IL-12, as well as inducing SIRS-like 
symptoms including: fever, hemodynamic abnormalities leukopenia, coagulation 
disorders, and increased production of liver enzymes[129].   
 
Interleukin-1:  IL-1 is another cytokine produced by monocytes in the acute 
phase of SIRS.   IL-1 has two subtypes; IL-1α, and IL-1β.  IL-1α is mainly found 
in the cellular compartment, while IL-1β is the predominant form found in 
circulation during sepsis[130]. There have been two receptors (IL receptor type I 
and IL receptor type II) identified for IL-1α and IL-1β.  The structural similarity of 
the molecules allows them both to activate each receptor type, although IL-1 
receptor type II is thought to be biologically inactive[119;119;130] which means 
that it may serve to negatively regulate IL-1 function.   IL-1 is not normally found 
in human plasma, and when endogenously or exogenously administered induces 
many of the same symptoms as TNFα[129].  The overlapping role of these 
cytokines is thought to create either a synergistic, or additive effect that amplifies 
the severity of the inflammatory response[123].  One effect of IL-1 is rapid 
activation of cytosolic phospholipase A2, which is an important molecule in 
conversion of tissue polyunsaturated fatty acids such as arachidonic acid (AA) to 
lipid-based inflammatory mediators[131].  This activation has been linked with an 
increased production of prostaglandin E2 (PGE2), which is recognized by the 
central nervous system triggering induction of fever[132].  Pretreatment with 
cyclooxygenase inhibitors decreases some of the symptoms, such as fever and 
headache, that are induced when IL-1 and TNFα are coadministered[133].  IL-1 
also induces production of other cytokines such as IL-1, IL-6, IL-8, as well as 
TNFα. Blocking activity of IL-1 using receptor antagonists can prevent the 
increase of other interleukins, but not TNFα[134].  IL-1 also up-regulates 
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production and expression of TNFRII which increases the effect of TNFα on 
cells[135].   
 
Interleukin-6:  IL-6 is a 21-kDA protein produced in many cell types, including 
monocytes.  IL-6 activates B and T lymphocytes[119].  IL-6 release from resident 
liver macrophages (Kupffer cells) signals the liver to produce acute phase 
proteins. This results in increased circulating coagulatory, transportation, and 
tissue remodeling factors, as well as decreased proteins from the cytochrome 
p450 complex. IL-6 also lowers circulating levels of cholesterol and fatty acids.  
IL-6 alters the carrier molecules of fatty acids by increasing their affinity with 
activated macrophages, thereby providing more energy to the immune 
response[122]. IL-6 has been shown to induce fever by stimulating PGE2 
production in the central nervous system[136].  IL-6 has also been shown to 
increase cytotoxicity of PMNs by augmenting release of elastase[137]. Although 
the role of IL-6 in sepsis is not as clearly defined as IL-1 or TNFα, an increase in 
IL-6 has a significant correlation with mortality in septic patients and severity of 
inflammation-associated organ dysfunction[119].   
 
Interleukin-8:   IL-8 is a small protein that is a member of the chemokine family of 
cytokines, is produced by a variety of cells, and is up-regulated by various factors 
such as LPS, TNFα, and IL-1[138].  The primary function of IL-8 is to activate 
and chemoattract PMNs to sites of inflammation[129].  IL-8 operates through 
CXCR1 and CXCR2 receptors, which are in the seven transmembrane G-
coupled protein receptor groups.  IL-8 interaction with PMNs causes shape 
change and increases cell surface expression of integrin molecules, increasing 
PMN adherence to vascular endothelium, as well as increasing production of 
reactive oxygen metabolites in PMNs[119].  
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Interleukin-12:  Proinflammatory IL-12 is a heterodimer consisting of a p35 and a 
p40 subunit, both of which are encoded by separate genes.  IL-12 production 
occurs predominantly in macrophages and monocytes and targets T cells and 
natural killer cells.  Activation of these cells by IL-12 induces production and 
release of interferonγ (IFN-γ), which acts on monocytes to increase production of 
proinflammatory cytokines including IL-12[119;130].  The role of IL-12 
heterodimer may enhance the inflammatory response by creating a positive 
feedback loop for cytokine production between T cells, natural killer cells, and 
macrophages.  
 
Anti-inflammatory Cytokine Cascade in SIRS/Sepsis: 
In order to prevent host mortality from an uncontrolled inflammatory response, an 
intricate system has evolved to attenuate the effects of the inflammatory 
cascade.  This system involves cytokines and signaling pathways that reduce 
production of proinflammatory mediators, soluble receptors that can bind 
inflammatory stimuli before it can interact with target cells, as well as cellular 
adaptations that reduce ability of cells to respond to stimuli. 
IL-10 is a homodimeric 160 amino acid protein produced by a variety of cells. IL-
10 inhibits production of TNFα, IL-1, and IL-8[129].  In PMNs, IL-10 reduces 
production of these proinflammatory cytokines in LPS-stimulated cells, enhances 
production of IL-1 receptor antagonists (IL-1ra), and reduces PMN migration 
during LPS induced lung injury[139].   
 
Interleukin-4:  IL-4 is a 20-kDa glycoprotein produced by activated Th2 cells, 
basophils, and mast cells.  IL-4 targets monocytes and PMNs and inhibits 
secretion of proinflammatory cytokines[119]. 
 
Interleukin-10:  Of the anti-inflammatory cytokines, IL-10 is perhaps the most well 
studied in models of bacterial infection.  IL-10 is an 18-kDa polypeptide that is 
synthesized by T cells, B cells, and monocytes.  IL-10 synthesis is stimulated by 
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TNFα, IL-1, IL-6, and IL-12, as well as bacteria and bacterial products such as 
LPS[130].  IL-10 production occurs maximally after about 24 hours in patients 
with severe sepsis, and has been shown to prevent LPS-associated mortality in 
laboratory animals[119]. 
 
Other anti-inflammatory cytokines:  Certain cytokines seem to serve dual roles in 
inflammatory regulation.  IL-6 for example, stimulates differentiation and 
proliferation of T cells, B cells, and induces acute phase protein synthesis. It 
inhibits IL-1 and TNFα production in monocytes[140], and induces production of 
IL-1 receptor antagonist and soluble TNFα receptors, which blocks effects of 
their proinflammatory ligands[141].  The p40 subunit of IL-12 has the ability to 
dimerize with the p35 subunit, or to form a homodimer with another p40 subunit.  
This homodimer of p40 subunits can bind to the IL-12 receptor with similar affinity 
as the p40/p35 complex without inducing a cellular response[130].   
 
Soluble Inhibitors of Proinflammatory Cytokines: Anti-inflammatory cytokines 
function by inhibiting production of their proinflammatory cousins.  However, 
there are also mechanisms to inhibit action of potentially toxic proinflammatory 
cytokines after they have been released from the cell.  
 
Soluble TNFα:  As previously mentioned, TNFα plays a major role in induction 
and maintenance of the inflammatory response.  TNFα works synergistically with 
IL-1 to activate other pro-inflammatory cytokines and to direct the host response 
to infection and injury; however, excessive tissue production of TNFα can cause 
detrimental effects.  Therefore, aside from a decrease in production caused by 
presence of anti-inflammatory cytokines, other mechanisms exist that blunt the 
effect of TNFα that is already present.  These natural inhibitors are the soluble 
TNFα receptors (sTNFR).  They are produced by numerous cell types as they 
shed the extracellular domains of their membrane bound TNFα receptors[142].  
This shedding can be induced by a number of stimuli, including IL-10, IL-1, and 
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TNFα itself[130].  There are two varieties of sTNFR, a 30-kDA and a 40-kDA 
species, which share sequence homology with extracellular domains of TNFRI 
and TNFRII, respectively[142].  The presence of sTNFRs serves a twofold 
purpose. First, shedding the extracellular portion of their TNFR effectively 
desensitizes cells to TNFα. Second, sTNFRs can still bind to the extracellular 
TNFα, preventing it from acting as a ligand for membrane bound TNFRs.   
 
Soluble and membrane bound IL-1 inhibitors and receptor antagonists: 
Like the mechanisms that exist for TNFα, there are several methods for limiting 
biological activity of circulating IL-1.  First, is the existence of a non-functional 
receptor, IL-1 receptor, type II, which binds to IL-1β with high affinity[130].  IL-1 
receptor type II exists in two forms, either as a membrane bound molecule, or as 
a soluble form.  Like sTNFR soluble IL-1 receptor type II is made up of the 
cleaved portion of the extracellular domain of its membrane bound 
counterpart[143].  This cleavage can be induced by a variety of stimuli including 
LPS and TNFα[144].  IL-1 receptor type II is a unique cytokine receptor because 
it does not provide signal transduction once bound to IL-1β.  This along with the 
high affinity to IL-1β allows both the soluble and membrane bound forms of IL-1 
receptor type II to act as a decoy to IL-1β[143].   
Another mechanism for decreasing the biological impact of IL-1 is IL-1 
receptor antagonist (IL-1ra).  IL-1ra is a 22-kDa protein that shares sequence 
homology with IL-1β.  IL-1ra binds preferentially to the active IL-1 receptor (IL-1 
receptor type I).  However, crucial sequence differences in IL-1ra prevent proper 
formation of the complex required to incite signal transduction once IL-1ra is 
bound[143]. 
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V.  Complications Secondary to Sepsis 
 
Multiple Organ Dysfunction Syndrome: 
As the severity of sepsis progresses it is not uncommon for organ dysfunction to 
occur.  In fact, the cause of death in most sepsis patients is not from infection, 
but from organ failure.  The occurrence of multiple organ failure during sepsis is 
so prevalent that the condition has been termed multiple organ dysfunction 
syndrome (MODS).   Organ dysfunction occurs when the functional status of that 
organ has been altered to the point that it is no longer able to maintain 
homeostasis.  This change is attributable either primarily or secondarily to insult, 
and this route determines whether MODS is defined as primary or secondary 
MODS.  In most cases of sepsis, MODS would be defined as secondary, as it is 
typically a result of host response to insult[120].  
 
Lung Injury in MODS:   
Lung dysfunction occurs in about 60% of septic patients with MODS[145].  The 
high incidence of lung involvement is due to several factors related to the organ 
and its function.  Because of the large interface of the lung with the external 
environment, it has developed an intricate and highly sensitive defense 
mechanism to protect against microbial invasion.  In this system two cell types 
have been identified as being vital for host defense; the alveolar macrophage 
and the PMN.  Resident alveolar macrophages have perhaps the most important 
role of any monocyte cell type in host defense of microbial invasion.  These cells 
are positioned within the surfactant layer of the alveolus.  They are directly 
responsible for detection and clearance of bacteria in the alveolar space[146].   
Aside from the direct antimicrobial role of the alveolar macrophage, this cell can 
recruit circulating PMNs to the alveolar lumen through a series of chemical 
mediators.  These mediators include protein derived cytokines as well as lipid 
derived eicosanoids.  Several recent studies have suggested that in models of 
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lung injury eicosanoid products play the predominant role in cell signaling.  This 
is based on findings that alveolar macrophages are capable of enhanced 
eicosanoid release as compared with monocytes or macrophages from other 
tissues[147].  Alveolar macrophages are primed for an increased production of 5-
LO eicosanoid products, specifically LTB4[41]. It is thought that this difference 
exists as a mechanism to expedite sequestration of PMNs to the site of bacterial 
invasion, as the enzymes responsible for eicosanoid synthesis are constitutively 
present and do not require de novo synthesis, as is the case for cytokine 
production enzymes.  Release of eicosanoid mediators swiftly induces the 
chemotaxis of circulating PMNs from the lung microvasculature to the alveolar 
lumen.  Once recruited, PMNs become activated by cytokines and eicosanoids.  
This activation leads to release of bactericidal and cytotoxic compounds, 
resulting in PMN-mediated tissue damage, setting the stage for lung injury.  
During sepsis the sensitivity and enhanced response of immune cells in the lung 
places this organ at higher risk of being involved in development of secondary 
MODS.  Like sepsis, lung dysfunction follows along a spectrum of severity.  The 
progression of tissue damage may lead to conditions known as acute lung injury 
(ALI), and in the most severe cases, acute respiratory distress syndrome 
(ARDS).  
  
Acute Lung Injury and Acute Respiratory Distress Syndrome:  
ALI is defined as a syndrome of inflammation and increased permeability that is 
associated with a constellation of clinical, radiologic, and physiologic 
abnormalities that cannot be explained by, but may coexist with, left atrial or 
pulmonary capillary hypertension[148].  Clinical diagnosis of ALI is determined by 
acute onset, PaO2/FiO2 levels of less than 300mm Hg regardless of positive-end 
expiratory pressure (PEEP), bilateral infiltrates observed on frontal chest 
radiographs, and a pulmonary artery wedge pressure of greater than 18mm Hg.  
As with SIRS, ALI is considered to be a disease that covers a broad spectrum of 
severity.  The most severe form of ALI is acute respiratory distress syndrome 
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(ARDS).  ARDS follows the same definition as ALI with the exception that the 
PaO2/FiO2 level must be less than 200mm Hg[148].    
 
Pathology of ARDS: 
ALI/ARDS progresses through three overlapping phases; exudative, proliferative, 
and fibrotic phases.   The exudative phase of ALI/ARDS is denoted by influx of 
protein-rich edema fluid into alveolar spaces, as well as increased local 
production of proinflammatory cytokines and eicosanoids such as LTB4, TNFα, 
IL-1, and IL-8 by pulmonary macrophages[149].  Release of these inflammatory 
signals is important for the development of ARDS.  Lungs extracted from patients 
that died during this phase are heavy and rigid, often weighing over 2000g.  The 
lungs also become discolored, turning from their normal color to a reddish-blue or 
grey hue[150;151].  Alterations in endothelial cell function begin to allow 
proteinaceous fluid to seep from the vasculature to the interstitial space. Fluid 
accumulation widens the interstitial space between the pulmonary epithelium and 
vascular endothelium.  This space is normally 2.2µm, which includes the 
basement membrane as well as specialized type 1 alveolar epithelial cells.  Type 
1 alveolar epithelial cells are flattened in appearance and typically compose 8% 
of lung epithelial parenchyma, while covering a surface area of approximately 
5098µm. Type 1 alveolar epithelial cells operate in conjunction with type 2 
alveolar epithelial cells, which are larger cuboidal cells that typically comprise 
about 16% of the alveolar parenchyma while only covering a surface area of 
about 183µm[151].  Type 2 alveolar epithelial cells produce surfactant, which is 
responsible for reduction of surface tension at the alveolus[150;152;153].  Both 
alveolar epithelial cell types are connected by tight cell junctions that form a 
relatively impermeable barrier.  Sodium and potassium pumps found on type 2 
alveolar epithelial cells actively transport ions from alveoli to pulmonary capillary 
beds.  These pumps operate in tandem with aquaporins found on type 1 alveolar 
epithelial cells facilitating fluid clearance during normal functioning[150;151;154].  
The interstitial distance and normal functioning of alveolar epithelial cells is 
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crucial for proper gas diffusion and fluid exchange.  As fluid accumulation in the 
interstitial space continues, the alveolar ducts themselves begin to dilate, 
decreasing the air spaces to less than 1mm.  Eventually, edema fluid infiltrates 
the alveolar lumen.  Histologically, this first appears as a hyaline membrane 
along the alveolar ducts.  This membrane consists of condensed plasma proteins 
and cell debris that have leaked into the alveolus.  This hyaline membrane is 
often associated with a selective early loss of adjacent epithelial cells[151].  As 
ALI/ARDS develops, activated PMNs appear in the pulmonary vasculature, 
interstitial spaces, and eventually in the alveolar lumen[149;150;155].  PMN 
activation leads to release of nitric oxide (NO) and reactive oxygen species, 
proteases, elastase, and collagenase.  These cytotoxic compounds are 
responsible for the damage caused to type 1 and type 2 alveolar epithelial cells. 
Type 1 alveolar epithelial cells are very susceptible to PMN-mediated damage, 
and significant loss leads to areas of exposed basement membrane and 
disruption of normal fluid exchange contributing to alveolar flooding[150-152]. 
  Following the exudative phase of lung injury is a period of tissue 
restructuring and overall lung remodeling known as the proliferative phase[150].  
The overall appearance of the lung during this phase is described as being a 
glistening pale grey color, having a very solid and slippery feel to it, and having 
very small air spaces that may even be absent in some areas[151].  A key 
feature of this phase is increased accumulation of interstitial myofibroblasts. 
Increased production of transforming growth factor β (TGFβ), and autocrine IL-
1β-dependant IL-6 up-regulation activates fibroblasts which, deposit collagenous 
connective tissue along the wall of the alveoli[156;157].  The increased amount 
of fibrous tissue in the alveolar septa leads to decreased airspace in the alveolar 
ducts and in the space of individual alveoli, further decreasing efficiency of gas 
exchange.  Lesions in alveolar epithelium from loss of type 1 alveolar epithelial 
cells allow fibroblast infiltration into the alveolar lumen.  Here the fibroblasts 
begin to convert the proteinaceous edema fluid into connective tissue through 
collagen deposition. This effectively converts areas that were previously air 
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spaces in the alveolar lumen to interstitial tissue.  Type 2 alveolar epithelial cells 
rapidly proliferate, and begin to differentiate into type 1 alveolar epithelial cells in 
an attempt to cover old basement membrane and newly deposited fibrotic 
connective tissue as well[150-152].   Another mechanism of lung remodeling is 
alveolar collapse.  This is observed after injury to the alveolocapillary unit, when 
the actual alveolar walls collapse either partially or completely.  Fibroblast 
infiltration and conversion of edema fluid to fibrotic tissue followed by epithelial 
cell growth effectively seals these areas from the rest of the lung.  This tissue 
remodeling leads to a lung that contains significantly fewer, but larger alveoli with 
dilated alveolar ducts as compared to the uninjured lung. 
The final stage, or the fibrotic stage, occurs 3-4 weeks following the onset 
of ARDS.  The lungs of surviving patients become heavily scarred, non-
compliant, end-stage organs, and is described as having a coarse, cobblestone 
surface due to heavy scarring and restructuring[150;151].  The parenchymal 
surface is pale and spongy, consisting of a honeycomb network of scar tissue 
and microcystic air spaces.  Microscopically alveolar walls are sparsely cellular 
and thickened by collagenous connective tissue[151]. 
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VI.  The Neutrophil 
 
The polymorphonuclear neutrophil (PMN) is considered to be the primary effector 
cell in innate immunity.  This cell type has evolved a variety of biological agents 
to aid in tissue transit and bacterial killing.  The PMN contains more than 30 
histotoxic agents, and has been implicated in the pathogenesis of numerous 
inflammatory disease states[158]. 
 
Role of PMNs in ARDS: 
The tissue damage and pathophysiology of ARDS is driven by an aggressive 
inflammatory response.  The initiation of this response is choreographed by the 
alveolar macrophage, which acts through various inflammatory mediators to 
rapidly recruit PMNs to lung tissue.  Recruited PMNs actively migrate to the site 
of infection or inflammation.  Bactericidal action of PMNs occurs by  phagocytosis 
of the invading organism, or by release of cytotoxic granules and reactive oxygen 
species into the extracellular environment[159].  During normal immune function 
specialized complexes within the PMN allow the cell to produce highly reactive 
oxygen species such as superoxide radicals, hydrogen peroxide, and hydroxyl 
radicals.  These compounds along with numerous proteases found in specialized 
granules and secretory vesicles are used to kill ingested microbes[160;161].  
PMNs can also release these granules and reactive oxygen species into the 
extracellular environment.  These compounds interact with microbes in a variety 
of manners, eliciting damage to their cell membranes, disabling key metabolic 
pathways, and causing damage to their DNA[159;162].  The critical role of the 
neutrophil in ARDS was first suggested in studies in which LPS injections were 
shown to increase PMN sequestration to pulmonary tissue[163], and that PMN 
depletion prior to insult could prevent ARDS symptoms[164].  Under normal 
circumstances PMNs constitute approximately 0.08% of the cell population found 
in the lung.  However, bronchoalveolar lavage fluid cell counts from patients with 
ARDS have demonstrated that the PMN population increases to constitute as 
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much as 70% of the cell population[165]. The release of potent neutrophil 
attractants and activating factors such as LTB4, IL-8, TNFα, IL-1, and IL-6 by 
resident alveolar macrophages stimulate the pulmonary microvascular 
sequestration and activation of PMNs.  There is some debate as to the control 
that the PMN has on the release of cytotoxic compounds upon activation.  There 
have been some reports in the literature that would indicate PMNs typically exert 
a fair amount of control in their response to stimulation[162], while others report 
that damage caused by PMNs is due to their lack of control mechanisms[145]. 
This makes the increased presence of PMNs in pulmonary tissue a key factor in 
the tissue damage and lung injury during SIRS/sepsis and ARDS 
[145;150;152;165].  Resolution of ARDS is highly dependent on clearance of 
PMNs from the lung, while preventing the release of cytotoxic contents of the 
cell.  Programmed cell death, or apoptosis plays a critical role in accomplishing 
this task.  Apoptotic PMNs lose their ability to produce and release cytotoxic 
compounds, and alveolar macrophages recognize specific signaling molecules 
that are present on the extracellular membranes of these dying cells.  
Macrophages phagocytize the apoptotic PMNs, preventing granule and 
superoxide release[166]. 
 
Granules and PMN Function: 
The specialized nature of PMNs as highly adaptable cells of immune function 
stems from their granules and secretory vesicles.  For decades it was believed 
that these structures, unique to PMNs, were simple storage compartments for 
bactericidal compounds.  Indeed, PMN granules contain a vast arsenal of 
proteolytic and oxidative chemicals that, when released into the extracellular 
environment or fused with the phagocytic vesicle, efficiently kill bacteria[162].  
However, the membrane portion of PMN granules and secretory vesicles contain 
numerous protein receptors and ligands that become expressed upon fusion of 
the granule with the cell membrane[161].   The expression of these factors allows 
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the PMN to effectively interact with the extracellular environment, transforming it 
from a passively circulating cell to an agent of the innate immune system.    
 
Neutrophil Activation: 
Neutrophils are highly specialized cells of immune function.  Features of these 
cells allow them to rapidly shift from a passive role as a component of the blood 
milieu, to aggressive and effective cytotoxic cells in presence of infected or 
inflamed tissue.  This process is mediated by several signaling cascades, 
including cytokine, chemokine, and eicosanoid release.  These factors initiate 
cellular changes that recruit, prime, and induce the cytotoxic activity of 
neutrophils.   
Neutrophil sequestration and activation occurs in a series of steps that 
alter form and function to allow them to first migrate to the site of infection or 
inflammatory stimulus and then to release their cytotoxic components to effect 
bacterial killing. There are a variety of stimulating factors that can interact with 
PMNs to effect these changes.   These can include bacterial products such as 
LPS, or cytokine or eicosanoid products released by macrophages.  Regardless 
of source, activation of PMNs induces cytokine production as well as 
physiological changes in the cells such as the up-regulation of adhesion 
molecules, alteration of PMN shape, and killing potential[167].  One of the effects 
of PMN activation by LPS is a change in the cytoskeletal structure of the cells 
that prevents them from being able to alter their shape to squeeze through small 
capillary beds.  It has been suggested that cytoskeletal alterations may play a 
role in the influx of some of the PMNS in the primary phase of ARDS. These 
PMNs become trapped in the pulmonary vasculature and begin releasing 
cytokines.  This cytokine release recruits more PMNs to the area, where they 
become activated and begin emigrating to the pulmonary parenchyma[167].   
Although LPS can directly exert an effect on PMN function, alveolar 
macrophages play a more prominent role as effectors of PMN function during 
sepsis and ARDS.  For example, IL-1 and TNF-α have both been shown to be 
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potent activators of PMNs.  These two cytokines operate through different 
surface receptor families that converge with induction of NFκB translocation to 
the nucleus leading to PMN activation[145;145;168].  PMN exposure to TNF-α 
leads to production and release of elastase, superoxide ion, hydrogen peroxide, 
soluble phospholipase A2 (sPLA2), platelet aggregating factor (PAF), 
thromboxane A2, and leukotriene production[145].  IL-1 has several overlapping 
effects on PMNs, stimulating production and release of elastase, collagenase, 
and prostaglandins.  Another factor in PMN infiltration of lung tissue is IL-8.  As 
previously mentioned IL-8 is a member of the chemokine family that is produced 
primarily in the lung by pulmonary macrophages and is a potent chemoattractant 
of PMNs.  IL-8 concentrations were higher in BAL fluid from hospitalized patients 
that subsequently developed ARDS as compared with those who did not fully 
develop the condition[169].   
 
Neutrophil Migration: 
The crucial role of PMNs as the primary defensive cell against microbial infection 
comes from the attribute of directed action and controlled release of cytotoxic 
granules at the site of inflammation.  The PMN inflammatory response is 
considered to be a multi-step process.  The first phase of PMN activation is the 
recruitment phase.  During this phase PMNs undergo an alteration of receptors 
and adhesion molecules expressed on the surface of the cells.  These alterations 
in the PMN membrane change the cells from passive circulating cells to active 
and potent participants in innate immunity.  PMN recruitment occurs in three 
distinct phases; rolling, firm adhesion, and finally extra-vascular migration[169].  
PMN recruitment involves a series of regulated exocytotic events involving 
intracellular granules and secretory vesicles that gradually change the functional 
state of PMNs[162].   
The rolling phase of PMN migration involves co-stimulation of vascular 
endothelium near the site of inflammation.  Activated vascular endothelial cells 
translocate P-selectin to their luminal membranes.  This endothelial cell ligand 
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activates P-selectin glycoprotein ligand-1 (PSGL-1) on the PMN.  The interaction 
between these ligands promotes PMN rolling along the endothelium[170].  
Activated endothelial cells also up-regulate E-selectin and the glycosylated cell 
adhesion molecules (glycams) that are ligands for PMN adhesion molecules 
CD15 and L-selectin, respectively[145;162;167].   
After the velocity of the circulating PMN has been slowed by interactions 
between selectins, a second series of adhesion molecules are expressed that 
form a firm adhesion between PMNs and activated vascular endothelial cells.  
This adhesion is mediated primarily by increased expression of the β2 integrin 
CD11/CD18 on the surface of the PMN.  CD11/CD18 is found in high 
concentrations along the membranes of secretory vesicles.  The mobilization of 
these vesicles during this phase enriches the surface of the PMN with 
CD11/CD18, while inducing shedding of L-selectin.  These changes allow 
interaction between the β2 integrins and intercellular adhesion molecules 
(ICAMs) found on the vascular endothelial cells, forming a firm adhesion between 
the PMN and vascular endothelium.  Interactions between CD11/CD18 and the 
ICAMs also prepare PMNs and local endothelial cells for 
extravasation[145;167;171]. 
The final step in PMN migration is extravascular migration to the site of 
inflammation.  Migration is directed by a number of factors, primarily the 
existence of a concentration gradient of chemoattractants that draw the PMN to 
the tissue.  This process is localized at endothelial cell junctions and involves 
platelet-endothelial cell adhesion molecule-1 (PECAM-1).  PECAM-1 is found in 
high concentrations in junctions between vascular endothelial cells.  It has been 
shown to act as a direct adhesion molecule for PMNs, and may also provide a 
measure of protection to preserve the permeability of vascular endothelium.  
Blocking PECAM-1 by monoclonal antibodies decreases PMN extravascular 
migration significantly[171;172].  Following migration through the junctions of 
vascular endothelial cells, PMNs release gelatinases, and collagenolytic 
metalloproteses that degrade the basement membrane surrounding blood 
 
 61
vessels.  As PMNs proceed toward the site of inflammation special matrix-
sensing receptors are expressed on the cell membrane.  These receptors 
choreograph release of collagenases and serine proteases that allow the PMN to 
effectively “drill” through the tissue toward chemotactic stimuli[145;162;165]. 
 
Cytotoxic Activity of PMNs: 
PMN mediated bacterial killing can occur by one of two mechanisms.  Primarily, 
PMNs act by engulfing microbes in a phagocytic vacuole.  Once internalized 
granules mobilize and merge with the membrane of the vacuole.  This allows 
release of granular contents into a controlled microenvironment.  Secondarily, 
mobilized granules and secretory vesicles interact with PMN cell membranes to 
exocytose their contents into the extracellular environment.  This second type of 
granule release is not only involved with bacterial killing, but is also an important 
mechanism by which the PMN migrates to sites of infection across extracellular 
tissue[162;167]. 
Upon reaching the site of infection PMNs have several tools at their 
disposal to kill invading microbes.  First, is an arsenal of proteolytic enzymes, 
which are stored in the granules of the PMN.  Granular storage protects the PMN 
from its own arsenal of cytotoxic compounds while providing a mechanism for a 
controlled response upon stimulation[158].  Fusion of these granules with either 
the cell membrane or the phagocytic vacuole causes release into the 
microenvironment.  As previously mentioned there are several granule types, 
each having different protein constituents for bacterial killing.  Primarily 
azurophilic granules contain high concentrations of myeloperoxidase, but also 
contain α-defensins, and bacterial permeability increasing protein[173]. These 
granules also have high concentrations of proteases such as proteinase 3, 
cathespin G, and elastase[161].  The α-defensins are small cationic antimicrobial 
and cytotoxic peptides that perforate the cell membrane leaving small multimeric 
holes[174].  Myeloperoxidase plays a vital role in the formation of reactive 
oxygen metabolites from NADPH oxidase-derived hydrogen peroxide[159].  
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Bacterial permeability increasing protein binds with membrane LPS on gram 
negative bacteria and causes a rearrangement of the lipids in the outer and inner 
membranes of the bacteria[175].  Proteases are examples of PMN components 
directed against tissue of the intercellular matrix.  These compounds quickly 
degrade components such as type IV collagen, vitronectin, fibronectin, and 
elastin.   
Specific and gelatinase granules contain high levels of bactericidal and 
matrix degrading proteins.  These include lysozyme, lactoferrin, and matrix 
metalloproteases[176-178].  Lysoszyme is a protease that is present in all 
granules; it is found in highest concentrations in the specific granules.  Lysozyme 
cleaves the peptidoglycan polymers of bacterial cell walls.  Lysozyme also acts 
as an anti-inflammatory agent by binding to LPS, and reducing its ability to bind 
with CD14 receptors.  Lactoferrin is found in specific granules, and impairs 
bacterial growth through a sequestration of Fe2+.  Matrix metalloproteases are 
found primarily in gelatinase granules.  These compounds include leukolysin and 
gelatinase, both of which are responsible for the degradation of the extracellular 
matrix.  These proteases are particularly effective against collagens, fibronectin, 
proteoglycans, lamnin, and gelatin.  Gelatinase granules are mobilized in 
response to activation of specialized matrix sensing receptors, allowing the PMN 
to tunnel to the site of infection[179].  Gelatinase, in particular, has been 
implicated for its role in the disruption of the alveolar basement membrane, and 
edema formation in ARDS[180].  
 The second mechanism by which PMNs deal with infection is by 
production of reactive oxygen species (ROS).  ROS production is managed by 
the NADPH oxidase enzyme complex[160].  In its native state the NADPH 
oxidase enzyme is stored in four separate parts.  The primary component, 
cytochrome b558 is found in abundance on the surface of specific granules.  
Cytochrome b558 becomes expressed on the phagocytic vacuole and the cell 
membrane following fusion with specific granules.  Cell activation also induces 
relocation of other constituents of the NADPH oxidase complex, p47phox, p67phox, 
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and p40phox, along with GTP binding protein to b558, thereby completing the 
complex[181].  Once assembled, the NADPH oxidase complex facilitates transfer 
of electrons from cytosolic NADPH to molecular oxygen in either the phagocytic 
vacuole or the extracellular environment.  This transfer is dependent on 
phosphorylation of p47phox at several serine residues.  This phosphorylation 
changes the structure of the molecule to allow a low affinity binding of NADPH.   
 Activation of the NADPH complex results in formation of superoxide (O2-) 
radicals, which are bactericidal in their own right, but interact with the 
myeloperoxidase enzyme complex to form hydrogen peroxide (H2O2).  This 
reaction accounts for the majority of the oxygen consumption observed during 
the respiratory burst of the PMN[159;182].  Myeloperoxidase can then use H2O2 
to oxidize a number of other molecules to form other reactive species.  One of 
the more unique ROS formed by myeloperoxidase activity is hypochlorous acid 
(HOCl).  HOCl is a strong non-radical oxidant of a wide range of biological 
compounds, and accounts for much of the bactericidal activity of ROS 
generation[183].  Further, HOCl along with superoxide radicals are used by 
myeloperoxidase to form an even more reactive compound, the hydroxyl radical.  
There is some debate as to the actual in vivo formation of these molecules by 
PMNs; however, they have been shown to be highly reactive with most biological 
compounds causing DNA modification and strand breaks, enzyme inactivation, 
and lipid peroxidation[159].  Myeloperxidase can also combine catalytically HOCl 
with amine groups to form chloramines.   Chloramines are long lived oxidants 
that react with thiols and thioesters.  The degradation of chloramines leads to the 
formation of toxic aldehyde compounds[159;160].   
 As illustrated here, PMNs posses a number of systems designed to 
destroy invading microorganisms.  During inflammatory conditions such as 
ARDS, in which there is an overabundance of PMNs these same compounds can 
cause massive damage to host tissue as well.  There are a number of theories as 
to why this occurs, one of which is the “Proteinase-antiproteinase balance theory” 
of PMN inflammation[158].  In order to avoid PMN-mediated tissue damage 
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during infection, host cells have developed several counteracting compounds 
that inactivate PMN-derived proteases and ROSs.  During acute PMN influx 
release of cytotoxic compounds effectively overwhelms the counterbalancing 
compounds and cause damage to host tissue.  Release of ROS and proteases 
by PMNs can either be intentionally via granule exocytosis or by loss of PMN 
membrane integrity during necrosis.  Apoptotic PMNs retain membrane integrity 
as assessed by vital dye exclusion assays.  Further, initiation of apoptosis in 
PMNs leads to a decrease in granule mobilization in response to stimulus.  In 
these regards, apoptosis plays a major role in PMN clearance without release of 
cytotoxic granules[102;184].   
 
Neutrophil Apoptosis and ARDS: 
The clearance of PMNs from the lung during ARDS or ALI without the release of 
cellular content is a vital step in the resolution of inflammation.  Recognition of 
apoptotic PMNs by alveolar macrophages triggers phagocytic engulfment of the 
PMN before membrane rupture occurs, resulting in spillage of cytotoxic 
compounds into the extracellular environment[185;186]. 
Neutrophil apoptosis represents the first step in clearance of inflammatory 
cells from areas of inflammation.  In order to prevent accidental release of 
cytotoxic compounds into the lung, alveolar macrophages can detect PMNs that 
are undergoing apoptosis.  Detection of these cells induces phagocytosis of 
PMNs by macrophages.  If not detected and engulfed, PMNs will undergo 
secondary necrosis.  This is associated with a loss in membrane integrity and a 
release of cytotoxic compounds.  This release is associated with detachment and 
death of human lung epithelial cells in vitro[187].  Phagocytosis of senescent 
PMNs prevents release of cytotoxic compounds into host tissue.  Apoptotic cell 
recognition by macrophages is still poorly understood, and several models have 
been suggested[186;188;189].  Macrophages have a large capacity for engulfing 
PMNs, which make them a major source of clearance for inflammatory cells.  
Phagocytosis of microbial particles induces production of proinflammatory 
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mediators such as TNFα, IL-1, etc., whereas phagocytosis of apoptotic PMNs by 
macrophages has also been shown to inhibit proinflammatory cytokine 
production, while increasing production of anti-inflammatory compounds such as 
PGE2, TGF-β, and PAF[188].  These findings emphasize the importance of 
apoptosis in the clearance of inflammatory cells and the resolution of 
inflammation.   This system of recognition is prone to disruption, however, and 
studies have shown that recognition of apoptotic PMNs can be decreased in low 
pH environments, or in presence of cationic molecules.  During conditions such 
as ARDS the presence of high numbers of PMNs can create such an 
environment, which could be one explanation for progression of the disease 
state[166]. 
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VII. Fatty Acids in ARDS 
 
Experiments from our lab by Mancuso et al. demonstrated that feeding diets 
supplemented with 20% fish oil for 21 days significantly attenuated lung 
permeability and hypotensive effects compared with control animals fed diets 
containing 20% corn oil for 21 days in LPS induced acute lung injury[72;73].  
These experiments also demonstrated that diets containing fish oil were able to 
significantly reduce concentrations of LTB4, PGE2, and TXB2 produced by 
macrophages collected from BAL fluid of animals and stimulated in vitro by the 
calcium ionophore, A23187.  These reductions were accompanied by decreased 
accumulation of AA in tissue phospholipids, along with increased EPA in animals 
fed diets containing fish oil[71].  Further studies by Mancuso demonstrated that 
fish oil diets could significantly reduce levels of myeloperoxidase activity in the 
lung when compared with animals fed a corn oil diet with LPS acute lung injury.  
Animals fed diets containing fish oil and administered LPS to induce lung injury 
also exhibited a reduction in the number of PMNs found in the BAL fluid when 
compared with animals fed the corn oil diet[72].  These studies culminated in 
clinical trials where patients were fed a custom high fat, low carbohydrate enteral 
nutrition formula containing a combination of fish and borage oils as well as 
antioxidants.  Patients fed this formula demonstrated a significant decrease in 
PMN accumulation in recovered BAL fluid as compared with patients fed an 
isocaloric, isonitrogenous diet deriving its main lipid content from corn oil.  
Accompanying the reduction in PMNs, patients fed the fish and borage oil diets 
demonstrated significant improvements in oxygenation, and significantly 
decreased dependence on ventilatory support.  These improvements resulted in 
a decreased stay time in the intensive care unit for patients fed the fish oil and 
borage oil supplemented diets when compared with controls[190].  Since 
eicosanoid products have been shown to be involved in regulation of PMN 
apoptosis, and their diets were shown to reduce the concentration of pro-
inflammatory eicosanoid products interest was raised as to the role that these 
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fatty acids might have on PMN lifespan[57].   Later work from our laboratory by 
Gillis investigated the possible interaction of diet and apoptosis using the human 
promyelocytic cell line HL-60[191;192].  The results of these experiments showed 
that direct treatment of HL-60 cells with either EPA or GLA ethyl esters alone or 
in combination would significantly decrease cell viability and that this decrease 
was through an increase in apoptosis[192].  Since previous work from our 
laboratory had demonstrated that decreased PMNs and symptoms of lung injury 
from endotoxic rats were accompanied by a significant reduction in eicosanoid 
products, we examined whether the effects of fatty acid treatment at inducing 
apoptosis in HL-60 cells could be replicated by inhibiting the pathways of 
eicosanoid metabolism[191].  These studies found that blockage of the 5-LO 
pathway, but not the COX pathways could induce apoptosis, implying a critical 
role for the products of 5-LO metabolism in the regulation of HL-60 cell 
apoptosis.  Taken together, these studies demonstrate the potential for n-3 fatty 
acids to influence the course of the inflammatory response in ARDS, and suggest 
that this impact could be due to an interaction between diet and neutrophil 
viability.   
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VIII. Summary of Literature and Introduction to Current Study 
 
Fatty acids of the n-6 and n-3 families are important substrates for the formation 
of inflammatory mediators.  The 20-carbon members of these families; AA and 
EPA, respectively, are competitive substrates for storage in cell membrane 
phospholipids and for the formation of eicosanoid products.  Eicosanoid products 
of AA are considered to be pro-inflammatory, and have been shown to have 
numerous effects including the chemotaxis and activation of PMNs.  Eicosanoid 
products of EPA are less biologically active than those from EPA, and are 
considered to be anti-inflammatory.  The addition of n-3 PUFAs to the diet 
reduces concentrations of n-6 PUFAs in the cell membrane and reduces the 
production of pro-inflammatory n-6-derived eicosanoids.   
 It has been suggested that an increased intake of n-3 fatty acids into the 
typical western diet may provide numerous health benefits.  However, due to 
concerns with safety and supplies of natural fish stocks these suggestions have 
been left largely unmet.  This has led to interest in identifying alternatives to fish 
oil for increasing n-3 fatty acid content in the diet.  Addition of ALA to the diet has 
been explored, but the conversion of ALA to EPA has been shown to be 
inefficient.  Thus, there is doubt as to whether dietary supplementation with ALA 
provides a suitable alternative to fish oil for increasing n-3 incorporation into 
tissue.  Recent developments in the agricultural industry have yielded crop plants 
that are capable of producing SDA in appreciable quantities, providing a potential 
renewable resource of n-3 PUFAs.   
Dietary supplementation with n-3 PUFAs from fish oil has demonstrated 
the ability to decrease eicosanoid concentrations and neutrophil accumulation in 
BAL fluid in patients and animals with ARDS or LPS-mediated acute lung injury.  
Reduction of neutrophil numbers in the lung has been correlated with improved 
outcomes in both patient and animal models.  It is not currently known if diets 
containing n-3 fatty acids affect neutrophil numbers by reducing neutrophil 
chemotaxis or by increasing neutrophil apoptosis.   
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This thesis has been designed to test two hypotheses; first, to examine if 
diets supplemented with SDA ethyl ester increases EPA content in liver 
phospholipids and if this increase is similar to those observed in animals fed a 
diet containing EPA.   Second, if dietary supplementation with SDA or EPA will 
impact the regulation of constitutive and endotoxin-induced survival in neutrophils 
by influencing the rate of apoptosis in both cell states. 
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I.  Materials and Methods 
 
Animals:  Male Long-Evans Rats (N = 18) weighing between 200-250g were 
acquired from Taconic (Germantown, NY).  Animals were housed at the animal 
care facility at The University of Tennessee Medical Center Knoxville at 
temperature ~24º C and on a 12h light: dark cycle.  After arrival at the animal 
care facility, rats were fed Harlan/Teklad 22/5 Rodent Diet (W) 8640 (Harlan 
Industries Indianapolis, IN) for 4 days before being placed into individual 
metabolic chambers for the feeding period of the study. Fresh water was 
provided ad libitum.  Animal weights and urine volumes were recorded daily.  
Food was withheld overnight before animals were killed.  All animal procedures 
were approved by The University of Tennessee Animal Care and Use Committee 
and were in accordance with the NIH Guide for the Care and Use of Laboratory 
Animals.         
 
Diets:  Animals were randomly divided into 3 dietary groups (n=6 animals/group) 
and were fed 200 kcal/ kg body weight/ day for 14 days.  All experimental diets 
were based on a typical western diet with the following caloric distribution: 
20.62% of calories from protein, 47.18% of calories from carbohydrates, and 
32.19% of calories from lipids.  This experimental diet mix was predicated on the 
US17 diet formulated by the Monsanto corporation (St. Louis, MO)[1] (Table 3.1).  
The experimental diets contained either 10g/kg (1%) eicosapentaenoic acid 
(EPA, 20:5; n-3, 95% pure) and 1% Trisun (ACH Humko, Cordova, TN) high oleic 
acid sunflower oil (OA, 18:1; n-9, 85% pure), or 10g/kg (1%) stearidonic acid 
(SDA, 18:4; n-3, 85% pure) and 1% Trisun high OA sunflower seed oil.  This 
design allowed fatty acids to be added at the expense of Trisun high oleic acid  
sunflower oil[1-3] without altering caloric density among diets.  Control diet, or 
OA diet, was prepared by adding 20g/kg (2%) Trisun to the base diet.  
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Table 3.1: 
Experimental Diet Composition 
  
 
 
Component  OA   EPA  SDA
(g/kg) (g/kg) (g/kg)
Casein 229 229 229
L-Cystein 3 3 3
Cornstarch 274 274 274
Maltodextrin 10 86 86 86
Sucrose 114 114 114
Cellulose 57 57 57
Cocoa Butter 43 43 43
Linseed Oil 5 5 5
Palm Oil 60 60 60
Safflower Oil 33 33 33
Sunflower Oil (Trisun) 20 10 10
20:5(n-3) ethyl ester (EPA) 0 10 0
18:4(n-3) ethyl ester (SDA) 0 0 10
Salt Mix RD-96 11 11 11
Dicalcium Phosphate 6 6 6
Calcium carbonate 19 19 19
Vitamin mix V134014 11 11 11
Choline bitartate 2 2 2
α-Vitamin E acetate 0.15 0.15 0.15
TBHQ 0.03 0.03 0.03
 kcal/kg protein 928 928 928
 kcal/kg carbohydrates 2124 2124 2124
 kcal/kg lipids 1449 1449 1449
total kcal/kg 4501 4501 4501
kcal/g chow 4.501 4.501 4.501
Carbohydrates Protein Lipids
Energy distribution (%) 47.2 20.6 32.2
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Diets had a final caloric density of 4.5kcal/g. All diets were mixed by hand under 
yellow light, and daily feedings were aliquoted into whirl-pak (Nasco, Ft. 
Atkinson, Wisconsin) containers, flushed with N2 gas to prevent peroxidation, and 
stored at -80º C until time of use.  Gas chromatography was used to confirm the 
fatty acid content of each diet[1-3] (Table 3.2). 
 
Cells:  All chemicals were purchased from Sigma Chemical (St. Louis, MO) 
unless otherwise noted.  Neutrophils were obtained by lavage from the peritoneal 
cavity after glycogen elicitation[4-6].  Rats were anesthetized with isoflurane 
(Abbott Labs, North Chicago, IL) and given a 30ml intraperitoneal injection of 1% 
type 2 oyster glycogen dissolved in 1x Dulbecco’s PBS without Ca2+ or Mg3+.  
Animals were allowed to recover for 4h and then re-anesthetized with isoflurane.  
A cardiac puncture was performed and animals were exsanguinated.  The 
musculature of the abdominal cavity was exposed through an incision in the skin 
and peritoneal lavage was performed using a 30ml syringe fitted with an 18 
gauge blunt tipped needle to flush the peritoneal cavity with 50ml of ice cold 1x 
Dulbecco’s PBS without Ca+2 or Mg+3 and with 1mM ETDA (Fluka Chemical, 
Switzerland) and 0.01% v/v heparin (American Pharmaceuticals Partners, Inc., 
Shaumburg, IL).  Lavage fluid was briefly agitated by massaging the abdominal 
wall and withdrawn from the opposite side.   Fluid was pooled in a 50mL conical 
centrifuge tube (Becton-Dickinson, Franklin, NJ) and peritoneal cells were 
pelleted by centrifuging at 700 x g for 7min in a Sorvall RT6000B refrigerated 
centrifuge (Sorvall, Newtown, CT).  Supernatant was carefully aspirated and 
contaminating red blood cells were removed by hypotonic lysis using 1ml 
pyrogen free cell culture water.  After 1 min of lysis, 0.5ml of 3x Dulbecco’s PBS 
was used to restore tonicity[7].  Cells were then resuspended in 50ml of 1x 
Dulbecco’s PBS.   Cell number and viability were assessed using a Neubauer 
hemacytometer and trypan blue dye exclusion assay.  Glycogen elicitation 
yielded > 98% pure neutrophil populations as evaluated during hemacytometry.  
Cell concentrations were adjusted to1 x106 cells/ml.  Cells for each incubation  
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Table 3.2: 
Experimental Diet Fatty Acid Composition. 
OA EPA SDA
Fatty Acid
12:0 0.36 0.33 0.34
14:0 0.56 0.52 0.53
16:0 26.09 25.21 25.15
16:1 0.17 0.17 0.16
17:0 0.13 0.12 0.12
18:0 12.75 12.16 12.13
18:1 (n-9) 35.06 31.2 31.21
18:2 (n-6) 20.23 19.82 19.69
18:3 (n-3) 2.1 2.05 2.05
18:4 (n-3) ND ND 5.26
20:0 0.56 0.54 0.53
20:1 0.14 0.13 0.12
20:4 (n-6) ND 0.18 ND
20:5 (n-3) ND 5.44 ND
22:0 0.24 0.2 0.2
22:6 (n-3) 0.13 0.11 0.11
ND indicates not detectable.
Dietary Groups
g/100g total fatty acids
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were separated and placed into 15ml conical centrifuge tubes (Becton Dickinson 
 containing 
ell Treatment and Incubation:  Cells from each feeding group were incubated 
ol 
 
ow cytometry: Cell preparation and staining for flow cytometric analysis of 
BD 
rvall 
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Labware, Franklin Lakes, NJ) and were pelleted by centrifugation at 700 x g for 
7min and resuspended at 1x 106 cells/ml in RPMI 1640 without phenol red and 
supplemented with 10% heat inactivated fetal bovine serum, 1% glucosamine, 
and 1% penicillin/ streptomycin.  Cells were transferred to 12x75mm 
polypropylene tubes (Becton Dickinson Labware, Franklin Lakes, NJ)
pre-warmed media and allowed to equilibrate. 
 
C
for 20h in either the presence or absence of 1µg/ml of Salmonella enteritidis 
lipopolysaccharide (LPS, Sigma Chemicals, St. Louis, MO).   A positive contr
for apoptosis was obtained by incubating cells for either 4 or 20h in presence of 
5µM camptothecin (CAM, Sigma Chemicals, St. Louis, MO). All treatment and 
control tubes were prepared in triplicate and contained a final concentration of 
250,000 cells/ml.  Atmosphere was maintained at 37º C and 5% CO2/ 95% room
air mix in a NAPCO 5410 incubator (Precision Scientific, Chicago, IL).   
  
Fl
apoptosis was performed using an Annexin-V FITC Apoptosis Detection Kit (
Pharmingen, San Diego, CA).  At 0 and 20h, cells from control and LPS 
treatment groups were pelleted by spinning at 700xg for 7 min using a So
RT6000B refrigerated centrifuge.  CAM treated cells were pelleted at 4h or 20h
but otherwise were handled identically to other treatments.  Supernatants were 
carefully removed and cells were resuspended in 1ml of PBS containing 0.1% 
bovine serum albumin (BSA).  Cells were transferred to 2ml polypropylene tube
and pelleted using a model 5415 D eppendorf centrifuge (Brinkmann Industries, 
Westbury, NY).  Supernatant was removed and 100µl of annexin-V binding buffe
(kit) was added to each tube.  Cells were mixed by flicking the side of the tube 
followed by addition of 5µl of annexin-V protein and 10µl of propidium iodide (P
(both from kit) in the dark.  Cells were then allowed to incubate for 15 min at 
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room temperature in the dark.   Following incubation, 400µl of annexin-V bind
buffer was added to each tube.  Cells were transferred to 12 x 75mm polystyrene 
tubes (Becton Dickinson Labware, Franklin Lakes, NJ), placed on ice and kept in 
the dark until analysis.  Flow cytometry was performed using a Becton-Dickinson 
FACScan flow cytometer and analyzed using Cell Quest software v. 1.2 (Becton 
Dickinson, San Jose, CA).   Unstained, PI positive/ annexin-V negative, and 
annexin-V positive/ PI negative cells were used to adjust gain and compensa
levels, as well as to properly adjust scatter plot and gate settings of the flow 
cytometer (figure 3.1).  The main cell population was isolated based on size a
complexity from the forward scatter and side scatter dot-plot.  This population 
was liberally gated to encompass viable, necrotic, and apoptotic PMNs, while 
excluding smaller aggregates and debris components.  FL-1 represents a typic
histogram representation of annexin-V fluorescence, while FL-2 represents a 
typical histogram of PI fluorescence.  Annexin-V positive and PI positive cells 
were defined by histogram markers.  M1 represents cells that exhibit either 
negative or dim fluorescence, which are considered negative for annexin-V o
respectively.  M2 represents brightly stained cells that are considered to be 
positively stained for either annexin-V or PI.  M3 region was used to calculate
number of cells that were only dimly stained (data not shown).  Figure 3.1 also 
illustrates a typical scatter-plot of cell fluorescence.  Each quadrant is labeled as
being either annexin-V +/- or PI +/-, and represents cell condition.  Cells in the 
lower left quadrant are considered viable since they were not stained with eithe
PI or annexin-V. The lower right quadrant contains cells that are PI negative and 
annexin-V positive and are considered apoptotic.  Cells in the upper right 
quadrant are cells that are positively stained for both annexin-V and PI.  S
dual staining indicates cells with DNA damage representative of apoptosis as 
well as PI permeable membranes these cells are defined as being secondary 
necrotic cells.  In vitro, secondary necrotic cells have been defined to be in the
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(A) Flow cytometric repres
    1     
 
igure 3.1. Settings and Representative Report From Flow Cytometry Analysis 
            
 
 
 
 
 
 
 
 
 
 
entation of forward scatter versus side scatter. 
          Red cells in Region R1 represent gated cell population used for analysis.
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B.  
  
             
 
(B) Fluorescence histogram of Annexin-V 
M1 represents unstain  annexin-V negative. 
 
               C.   
 
 
M1 repre ered PI 
Figure 3.1. Continued. 
 
 
 
 
                
 
 
 
  
ed or dimly stained cells that were considered
M2 represents brightly stained cells that were considered 
annexin-V positive. 
 
  
 
 
 
  
 
 
 
(C) Fluorescence Histogram of propidium iodide. 
sents unstained or dimly stained cells that were consid
e.M2 represents brightly stained cells that were considenegativ red PI 
positive.M3 was used to calculate dimly stained cells (data not shown). 
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igure 3.1. Continued. 
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(D) Scatter-plot representation of cell staining. 
PI- ANNEXIN – represents unstained viable cells. 
eNNEXIN + represents annexin stained apoptotic c
EXIN + represents dually stained secondary necrotANN ic ce
PI+ ANNEXIN – represents PI stained necrotic cells. 
 
 
 
F
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phase following apoptosis[8]. Finally cells in the upper left quadrant are 
considered to be necrotic, as their membranes have been permeablized to PI 
without occurrence of DNA cleavage.  The lower right and upper right quadrants 
were also combined to determine the total number annexin-V stained cells 
regardless of PI staining.  These cells were considered to represent those both 
actively undergoing apoptosis, as well as those that had previously died through 
the apoptotic route.  This data set was termed “cell death”. 
 
DNA Laddering:  Presence of apoptosis in peritoneal cells from animals from 
each feeding group (n=2) was confirmed by agarose gel electrophoresis[9].   For 
each gel 1x106 cells from 0h or from 20h treatment groups were transferred into 
2ml snap-top eppendorf tubes.  Cells were pelleted at 700 x g for 7min using an 
eppendorf centrifuge, model 5415D (Brinkmann instruments, Westbury, NY), the 
supernatant was carefully removed, and cell pellets were flash frozen in liquid 
nitrogen.  Cells were stored at -80º C until analysis.  On day of analysis, cells 
were allowed to thaw for ~5min and 20µl of lysis buffer (20mM EDTA 
(Mallinckrodt, St. Louis, MO), 100mM TRIS, pH 8.0, 0.8% (w/v) sodium lauryl 
sarcosine (Bioworld, Dublin, OH)) was added to each tube.  Immediately 
following addition of lysis buffer 10µL of 1mg/ml RNase/T1 cocktail mix (Ambion, 
Austin, TX) was added, and samples were mixed and incubated for 75min at 
37ºC.  Proteinase K 10µl (Ambion, Austin, TX) was added to cell lysates which 
were then incubated for 120min at 50º C.  Samples were mixed with 5µl loading 
buffer and loaded onto a 1.5% agarose gel.  Gel was run for 200min at 30v in 1x 
TAE buffer using Bio-Rad Mini-Sub Cell GT (Bio-Rad, Hercules, CA) and a 
Fisher Biotech FB300 (Fisher Scientific, Pittsburgh, PA) power supply.  Molecular 
marker XIV (Roche, Manheim, Germany) was used as a reference for DNA 
fragment size.  Cells were exposed to a 4h CAM treatment as a positive control 
for apoptosis.  DNA bands were visualized using ethidium bromide (Promega, 
Madison, WI) on a Fluorchem 8000 Imager (Alpha Innotech, San Leandro, CA).  
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TUNEL Assay:  Detection of apoptosis by TUNEL assay was performed using 
the In Situ Cell Death Detection Kit, Fluorescein (Roche, Manheim, Germany). At 
0h and for both control and LPS treatment groups at 20h approximately 20,000 
cells were cytospun for 5 min at 500 rpm (Cytospin3, Shandon, England) and 
placed onto glass microscope slides (Fisher Scientific, Pittsburgh, PA).  Slides 
were air dried and fixed for 1h using Carson’s solution.  Slides were then rinsed 
using PBS and placed in drying racks and stored until analysis.  On day of 
analysis, slides were rinsed with PBS and 100µl of cytofix/cytoperm solution 
(Pharmingen, San Diego, CA) was applied.  Slides were incubated for 20min at 
4º C and washed with 100µl perm/wash buffer (Pharmingen, San Diego, CA).  
Slides were rinsed with deionized water, allowed to air dry, and stained for 
apoptosis using 50µl TUNEL reaction mixture (kit) and incubated for 60min at 37º 
C in a humidified chamber.  100µl of Hoechst stain (Molecular Probes, Eugene, 
OR) was applied to each slide as a counter stain to detect total DNA.  Slides 
were incubated for 30min at 37º and rinsed with PBS. Protective 12 x 50 – 1.5 
glass coverslips (Fisher Scientific, Pittsburgh, PA) were applied using Dako 
fluorescent mounting medium (Dakocytomation, Carpinteria, CA).  Slides were 
viewed using an Olympus BX51 fluorescent microscope (Olympus Optical Co., 
LTD., Japan) under both FITC and DAPI filters.  Images were captured using a 
Magmafire SP CCD camera (Optronics, Goleta, CA).  Image overlay and 
analysis was performed using Image-Pro Plus software v 4.5 (Media 
Cybernetics, Silver Spring, MD).        
 
Liver:  Following peritoneal lavage a central incision was made along the linea 
alba exposing the abdominal cavity.  The portal vein was located and separated 
from surrounding connective tissue; ligated using Silk suture (3-0, Ethicon, 
Somerville, NJ), and liver was perfused with 30cc ice cold PBS using an 18 
guage needle.  Liver sections ranging from 1-1.5g were removed and placed in 
50ml conical centrifuge tubes, labeled, and flash frozen using liquid nitrogen.  
Liver sections were stored at -80º C until time of analysis. 
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Total Liver Fatty Acid Extraction and Phospholipid Separation:  Total liver fatty 
acids were extracted using a modified Bligh and Dyer technique[10-12].  
Approximately 200mg of liver from individual animals was placed in a tissue 
homogenizer along with 1ml 0.9% cold saline/ 100mg liver.  Tissue was 
thoroughly homogenized and 0.8ml of homogenate was transferred into 
125x16mm Teflon coated screw top tubes (Corning, New York, NY).  
Chloroform:methanol (3ml,1:2) was added to each tube along with 44µg of 1,2-
diheptadecaenoic-sn-glycerol phosphorycholine (Matreya Biochemicals, Pleasant 
Gap, PA) as an internal standard.  Homogenate solution was vortexed and 
incubated for 30 min on ice in the dark.  Following incubation, 200µl saturated 
NaCl and 1mL chloroform was added to each tube.  Tubes were vortexed and 
incubated for 15 min on ice in the dark followed by centrifugation for 4 min at 
900x g to ensure complete phase separation. The bottom chloroform layer was 
transferred to a 12x75mm borosilicate glass tube (Fisher Scientific, Pittsburgh, 
PA) using a glass Pasteur pipette. The extraction and transfer process was 
repeated and samples were completely evaporated under nitrogen.  Once both 
extractions had dried completely they were reconstituted in 50µl chloroform, 
vortexed, and added to pre-scored silica gel 60 HP-TLC plates (Merck, 
Darmstadt, Germany) for separation of the phospholipid portion by thin layer 
chromatography (TLC).  Plates were placed in a TLC chamber containing 
approximately 1 inch of chloroform:methanol (8:1) as a mobile solvent system 
and ran for 15 min.  Plates were removed and allowed to dry fully under nitrogen.  
The phospholipid portion of each lane was scraped onto weighing paper and 
added to 16x125mm screw top tubes. 
 
Analysis of Phospholipid Fatty Acids:  Liver phospholipids were prepared for 
analysis by gas chromatography (GC)[2;10;12]by first saponifying with 0.4ml of 
0.5N NaOH/MeOH for 15 min in an 86º C water bath in tightly sealed 16 x 125 
mm screw top tubes. Tubes were then removed from the water bath and allowed 
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to cool. Fatty acids were methylated by adding 1ml of boron trifluoride/methanol, 
tightly recapping tubes, and incubating in an 86º C water bath for 10 min.  
Samples were removed from the water bath, allowed to cool, and acidified with 
0.4ml of 0.7 N HCl in MeOH.  Following acidification, fatty acid methyl esters 
were extracted once again by adding 2ml of hexane and 2ml of saturated NaCl 
solution to each tube.  Tubes were vortexed and allowed to settle for 
approximately 5 min for phase separation to occur. Samples were centrifuged for 
4 min at 900 x g for complete separation. The hexane (top) layer was carefully 
transferred to a new 12 x 75mm borosilicate tube for each sample.  A second 
hexane extraction was performed and pooled with the first and both extractions 
were completely evaporated under N2 gas.  Dried samples were reconstituted in 
100µl of hexane and vortexed vigorously.  Samples were analyzed using a 
Hewlett-Packard model 5890 series II gas chromatograph equipped with flame 
ionization detector and DB23 fused silica capillary column (0.25 mm i.d. x 30m x 
0.25µm film; J&W Scientific, Folsom, CA). Fatty acid separation was achieved by 
increasing temperature from 160-250º at a rate of 3.5º C / min using hydrogen as 
the carrier gas.  Gas chromatography standards 461 and 68B (Nu-Chek Prep, 
Elysian, MN) were included in each analysis procedure.  Retention times for the 
known standards were used to identify fatty acid methyl esters.  
Lipid Analysis of Diets:  The fatty acid composition of each diet was confirmed 
using gas chromatography.  Approximately 50mg of diet was placed into a 16 x 
125mm tube along with 3ml chloroform:methanol (8:1) and 44µg of 1,2-
diheptadecaenoic-sn-glycerol phosphorycholine as an internal standard and 
incubated on ice in the dark for 30 min.  Solid portions of food were separated by 
centrifugation and fatty acids from diets were extracted using the modified Bligh 
and Dyer technique[11] and analyzed using gas chromatography following the 
same protocol as outlined for liver phospholipids. 
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Statistical Analysis:  Data were expressed as mean ± SEM.  Fatty acid data were 
analyzed by one-way ANOVA followed by Ryan-Einot-Gabriel-Welch based on 
ANOVA F test (REGWF) to determine differences among groups.  Analyses were 
performed using CRUNCH v. 4.0 statistical package (Crunch Software Corp., 
Oakland, CA). Animal weight data were analyzed by repeated measures ANOVA 
followed by Wilk’s Lambda multivariate post-hoc test.  Flow cytometry data were 
used to determine effect of LPS treatment, diet, and interaction between diet and 
LPS treatment in altering the number of viable cells, cells undergoing early or late 
apoptosis, or cell death after 20h.  Flow cytometry data were analyzed using 
repeated measures ANOVA followed by Wilk’s Lambda multivariate post-hoc 
test. Analyses were performed using SPSS v. 13.0 for windows (SPSS inc., 
Chicago, IL). P≤0.05 was considered significant. 
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I. Results 
 
Animal Weights:  Body weights were recorded daily and reported as percent of 
body weight taken on the first day.  Repeated measures ANOVA indicated no 
differences in weight during the feeding period (figure 4.1).   
 
Liver Fatty Acid Composition:  Liver phospholipid fatty acid composition was 
determined after 14 days of feeding and reported as mol % (table 4.1).  
Alterations in liver phospholipids reflected fatty acid supplementation.  As 
compared with dietary OA, animals fed the EPA diet demonstrated a significant 
decrease in tissue AA levels (p≤0.05).  There was a significant increase in tissue 
EPA content for animals in the EPA group, as compared with those from the OA 
group (p≤0.05).  EPA-fed animals demonstrated a significant increase in tissue 
DPA, as compared with controls (p≤0.05). Supplementation of the diet with EPA 
failed to increase DHA levels as compared with OA fed animals.  EPA animals 
exhibited a significant increase in total n-3 fatty acid content, as compared with 
control animals (p≤0.05).  This was accompanied by a significant decrease in 
total n-6 fatty acid content of membrane phospholipids as compared with controls 
(p≤0.05).  These changes were reflected by an increased ratio of (n-3)/(n-6) fatty 
acids for animals in the EPA group as compared with OA animals (p≤0.05). The 
increased ratio of (n-3)/(n-6) PUFAs coincided with a significant increase in the 
membrane phospholipid ratio of EPA/AA in animals from the EPA group as 
compared with controls (p≤0.05).     
Dietary SDA produced similar results to those observed in EPA-fed 
animals in regards to fatty acid composition of membrane phospholipids.  Dietary 
SDA supplementation exhibited a slight, although not significant, decrease in AA 
content of membrane phospholipids as compared with OA diets.  SDA did, 
however, produce a significant increase in phospholipid levels of EPA as 
compared with dietary controls (p≤0.05).  SDA also significantly increased the  
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Figure 4.1. Effect of Diet on Animal Weight  
1Data are expressed as mean % initial body weight ± SEM 
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Table 4.1: 
Fatty Acid Composition of Rat Liver Tissue After Feeding Experimental Diets for 
2 Weeks. 
OA (n =7) EPA (n = 8) SDA (n = 7)
16:0
16:1
18:0
18:1 n-9
18:1 n-7
18:2 n-6
20:3 n-6
20:4 n-6
20:5 n-3
22:4 n-6
22:5 n-6
22:5 n-3
22:6 n-3
Total (n-3) FA
Total (n-6) FA
(n-3)/(n-6) ra tio
Data are expressed as mean mole % ± SEM. ND indicates not detectable.
Values with different superscripts indicate significant difference (p<0.05). n indicates number of animals.
8.86 ± 0.37b
43.83 ± 0.25ab
0.2 ± 0.01c
0.02 ± 0.00a
0.14 ± 0.04b
0.09 ± 0.02ab
1.03 ± 0.02c
7.12 ± 0.42
0.26 ± 0.01
0.52 ± 0.03
27.48 ± 0.47a
0.62 ± 0.07c
0.1 ± 0.02
0.08 ± 0.01
ND
0.08 ± 0.02
26.07 ± 0.23
3.32 ± 0.23
1.49 ± 0.03
15.5 ± 0.51
0.10 ± 0.27
15.99 ± 0.41 15.93 ± 0.42
0.14 ± 0.03
16.41 ± 0.12
1.50 ± 0.05
3.50 ± 0.13
25.78 ± 0.33
0.15 ± 0.01b
1.18 ± 0.17b
25.64 ± 0.39b
0.49 ± 0.02
9.9 ± 0.35b
6.96 ± 0.25
1.69 ± 0.10b
0.04 ± 0.05b
44.52 ± 0.28a
0.17 ± 0.01a
0.01 ± 0.00a
0.23 ± 0.01b
42.84 ± 0.45b
0.09 ± 0.02
0.56 ± 0.04
28.35 ± 0.56a
0.21 ± 0.05a
20:1
0.01 ± 0.01
0.07 ± 0.01
16.08 ± 0.37
0.06 ± 0.03
26.04 ± 0.25
3.73 ± 0.2
1.55 ± 0.05
15.06 ± 0.55
0.11 ± 0.0218:3(n-6)
18:3 (n-3)
Fatty Acid
20:0
0.11± 0.02
0.07 ± 0.02
0.02 ± 0.01
0.07 ± 0.02
EPA/AA ratio
0.29 ± 0.01
0.05 ± 0.01b
20:2 0.3 ± 0.05
0.30 ± 0.02a
0.14 ± 0.02a
0.51 ± 0.04a
6.84 ± 0.36
7.65 ± 0.41a
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DPA content of membrane phospholipids of the liver as compared with animals 
from the OA group (p≤0.05).  Dietary supplementation with SDA did not result in 
a significant increase in tissue DHA levels. Although diets containing SDA 
significantly altered some of the n-6 fatty acids, these changes did not result in a 
significant decrease of total n-6 levels as compared with controls.  However, 
there was a significant increase in the total n-3 PUFA content of membrane 
phospholipids of SDA animals as compared with OA fed animals (p≤0.05).  This 
was reflected by a slight, but significant, increase in the n-3/n-6 fatty acid ratio in 
membrane phospholipids of SDA-fed animals as compared with controls 
(p≤0.05). SDA did not significantly alter ratio of EPA/AA in the membrane 
phospholipids as compared with control animals. 
Addition of SDA or EPA to the diet resulted in an increase in the amount of 
EPA incorporated into membrane phospholipids in the liver.  Dietary SDA was 
approximately half as effective as dietary EPA at increasing membrane 
phospholipid EPA levels.  Diets supplemented with SDA were about two-thirds as 
effective as those containing EPA at increasing tissue DPA content above those 
observed in controls.  Neither the SDA nor the EPA diet produced a significant 
increase in tissue DHA levels. 
 
DNA Laddering:  During apoptosis DNA is degraded by endogenous DNases into 
180-200bp fragments, and presents a distinct banding pattern when examined 
using gel electrophoresis.  In this study, gel electrophoresis was used to confirm 
the presence of DNA cleavage, which is indicative of cellular apoptosis.  Results 
shown in Figure (4.2), although not quantitative, provide evidence that after 20h 
of incubation a number of cells had undergone apoptosis.  This banding was 
present regardless of diet or treatment with LPS.  The only lanes in which 
banding patterns indicative of DNA fragmentation were absent were those 
containing cells that were collected at 0h.   
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Figure 4.2. Effect of Diet and LPS Treatment on DNA 
Fragmentation.
Lanes: M=marker lane containing a 100bp ladder of DNA fragments 
from 2642bp, 1500-100bp; 1=PMNs from OA fed animal at 0h 
(negative control); 2=OA 20h –LPS; 3=OA 20h+ LPS; 4=OA cells 4h 
+ CAM (positive control);5=EPA 20h –LPS; 6=EPA 20h +LPS; 
7=SDA 20h –LPS; SDA 20 +LPS  
M 1 2 3 4 5 6 7 8
2462
1500
500
1000
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TUNEL assay:  Examination of slides prepared with both TUNEL and Hoechst 
stains confirmed the presence of apoptotic bodies among cell populations from 
all feeding groups.  Representative images from fluorescence microscopic 
examination of stained slides are shown in figure 4.3.  These images were 
created by overlaying digital pictures of a single area of a microscope slide taken 
under both DAPI and FITC filters.  Hoechst stained cell nuclei were used to 
provide a reference point for regions of the slide that were TUNEL positive.  
Images shown were taken from slides prepared with cells that had been 
incubated for 20h in either presence or absence of LPS.   Gross examination of 
slides indicated that treatment of cells with LPS for 20h led to an apparent 
decrease in the amount of bodies that were positive for TUNEL stain.  Slides of 
cells treated for 20h with LPS also appeared to be more densely populated with 
Hoechst positive bodies. Under gross examination, slides prepared with cells 
from animals that were fed either the EPA or the SDA diets also appeared to 
have fewer apoptotic bodies as compared with those from animals fed the OA 
diet.     
 
Flow Cytometry:  The effect of LPS on viability, apoptosis, secondary necrosis, 
and cell death in glycogen-elicited neutrophils after dietary treatment is shown in 
Figure 4.4 (A-D).  After 20h incubation diet did not significantly alter viability or 
LPS-mediated viability in neutrophils.  Because there was no interaction between 
diet and neutrophil viability we examined whether treatment with LPS had any 
effect on neutrophil survival, irrespective of diet.  The effect of LPS treatment, 
regardless of diet, on viability, apoptosis, secondary necrosis, and cell death are 
shown in figure 4.5 (A-D).  We show that, independent of diet, LPS significantly 
increased viability and decreased cell death due to a decrease in apoptosis and 
secondary necrosis.  Since apoptosis, secondary necrosis, and cell death at 20 
hours of incubation are directly related to freshly isolated (basal) values of these 
same parameters (basal data not shown), the absolute differences between the 
basal and 20 hr in absence and presence of LPS were calculated irrespective of  
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OA  
           A. 20h –LPS 100x                                                     B. 20h +LPS 100x 
 
 
 
 
 
 
 
 
 
 
EPA 
 
         C. 20h –LPS 100x                                                       D. 20h +LPS 100x 
 
 
 
 
 
 
 
 
 
 
       
SDA 
 
          E. 20h –LPS 100x                                                       F. 20h + LPS 100x 
 
Figure 4.3. Fluorescence Images of TUNEL and Hoechst Stained Cells From 
Each Feeding Group After 20h Incubation in Absence or Presence of LPS. 
A. Oleic acid group 20h –LPS; B. Oleic Acid group + LPS; C. EPA group –LPS; D. EPA 
group +LPS; E. SDA group –LPS; F. SDA group +LPS  
 
 
 
 122
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. (A-D).  Effects of Diet and LPS Treatment on Cell Viability, Apoptosis, 
Secondary Necrosis, and Cell Death in Glycogen Elicited Peritoneal Neutrophils 
at 20 Hours in Presence or Absence of LPS. 
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(A-B)  Effects of diet and LPS treatment on cell viability and apoptosis in 
glycogen elicited peritoneal neutrophils at 20 hours in 
presence or absence of LPS. 
1Mean ± SEM of cell population at 20h in presence or absence of LPS for  
cell viability and apoptosis as measured using flow cytometry with propidium iodide and  
annexin-V staining (N=6/group).
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(C-D)  Effects of diet and LPS treatment on secondary necrosis and cell death 
inglycogen elicited peritoneal neutrophils at 20 hours in 
presence or absence of LPS. 
1Mean ± SEM of cell population at 20h in presence or absence of LPS for 
secondary necrosis and cell death as measured using flow cytometry with propidium iodide and
annexin-V staining (N=6/group).
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Figure 4.5 (A-D). Effect of LPS on Viability, Apoptosis, Secondary Necrosis, and 
Cell Death Following 20h Incubation.
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(A-B) Effect of LPS on viability, apoptosis, secondary necrosis, and cell death 
following 20h incubation. 
*Values sharing different superscripts are different (p≤0.05) 
1Mean ± SEM of % cell population as measured by flow cytometry using annexin-v and propidium 
iodide staining (N=18). 
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(C-D) Effect of LPS on viability, apoptosis, secondary necrosis, and cell death 
following 20h incubation. 
*Values sharing different superscripts are different (p≤0.05) 
1Mean ± SEM of % cell population as measured by flow cytometry using annexin-v and propidium 
iodide staining (n=18). 
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 diet. Figure 4.6 (A-C) shows that apoptosis, secondary necrosis, and cell death 
were significantly decreased in the presence of LPS after correction, or 
normalization, for basal values and are in agreement with the findings shown in 
Figure 4.5 (A-D).   
The effect of dietary treatment on viability, apoptosis, secondary necrosis 
and cell death of freshly extracted glycogen-elicited neutrophils is shown in 
Figure 4.7 (A-D).  These results show that after two weeks of dietary treatment 
there were no significant changes in viability, apoptosis, secondary necrosis, and 
cell death between the groups.  It is important to note that although it appears 
that secondary necrosis and cell death with EPA were increased as compared 
with OA, statistical significance was not reached (P = 0.053).  Since apoptosis, 
secondary necrosis, and cell death at 20 hours of incubation are directly related 
to the basal values of these same parameters, the absolute differences between 
basal and 20 hr incubations in the absence and presence of LPS were calculated 
for each dietary treatment group.  The results indicate that neither SDA nor EPA 
significantly affected viability, apoptosis, and secondary necrosis as compared 
with OA in the absence or presence of LPS (Figure 4.8 (A-D)).   
Although, there appears to be an increase in cell viability with EPA and SDA as 
compared with OA in the presence or absence of LPS, these changes were not 
significantly different (p=0.069)            
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Figure 4.6. Effect of LPS on the Absolute Difference Between 0h and 20h for 
Apoptosis, Secondary Necrosis, and Cell Death  
Following 20h Incubation. 
*Values sharing different superscripts are different (p≤0.05) 
1Mean ± SEM of the difference of cell population % from time 0h for apoptosis, secondary 
necrosis, and cell death as measured using flow cytometry with propidium iodide and annexin-V 
staining (N=18). 
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Figure 4.7 (A-D).  Effect of Diet on Cell Viability, Apoptosis, and Secondary 
Necrosis in Glycogen-Elicited Peritoneal Neutrophils at 0 Hours. 
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(A-B)  Effect of diet on cell viability, apoptosis in glycogen-elicited peritoneal 
neutrophils at 0 hours. 
a,b Values sharing different superscripts are different (p?0.05) 
1Mean ± SEM cell population % at 0h for cell viability, apoptosis, and secondary necrosis as 
measured using flow cytometry with propidium iodide and annexin-V staining (N=6/group). 
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(C-D)  Effect of diet on secondary necrosis and cell death in glycogen-elicited 
peritoneal neutrophils at 0 hours. 
*Values sharing different superscripts are different (p≤0.05) 
1Mean ± SEM cell population % at 0h for cell death as measured using flow cytometry with 
propidium iodide and annexin-V staining (N=6/group). 
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Figure 4.8. (A-D). Effect of Diet on the Absolute Difference From Time 0h to 20h 
for Viability, Apoptosis, Secondary Necrosis and Cell Death Following 20h 
Incubation in Presence or Absence of LPS. 
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(A-B) Effect of diet on absolute difference from time 0h to 20h for viability and 
apoptosis following 20h incubation in presence or absence of LPS. 
1Mean ± SEM of the difference of cell population % from time 0h for apoptosis, secondary 
necrosis, and cell death as measured using flow cytometry with propidium iodide and annexin-V 
staining. 
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(C-D)  Effect of diet on absolute difference from time 0h to 20h for  secondary 
necrosis and cell death following 20h incubation in presence or absence of LPS.
1Mean ± SEM of the difference of cell population % from time 0h for apoptosis, secondary 
necrosis, and cell death as measured using flow cytometry with propidium iodide and annexin-V 
staining.
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Part 5 
Discussion 
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I. Discussion 
 
The results of this study show that feeding purified ethyl esters of EPA and SDA 
in the context of a typical western diet for 14 days resulted in the incorporation of 
n-3 fatty acids in the phospholipids of rat liver.  The diets used in this study were 
designed based on the macronutrient and fatty acid composition of a typical 
western diet.  Petrik et al[1] showed that by using oleic acid (OA) as the control 
fatty acid, they could maintain constant levels of n-6 fatty acids in their diets.  
They previously showed that OA is neutral in respect to prostaglandin 
formation[2].   OA is an n-9 fatty acid, and is not interconvertible with n-6 or n-3 
fatty acids.  We also designed our experimental diets using OA as the control 
fatty acid.  Our experimental diets were supplemented with purified ethyl esters 
of EPA or SDA instead of fish or an SDA containing oil such as echium oil[3].  
Thus, our design allowed us to vary fatty acid intake in the context of the typical 
western diet and avoid the problems of one dietary oil substituted for another.  
The results of this study can be attributed to substitution of one fatty acid for 
another. 
Dietary supplementation with purified SDA and EPA ethyl esters resulted 
in a significant increase in tissue phospholipid incorporation of n-3 PUFAs, such 
as EPA and DPA, in liver.   We found that supplementation with SDA resulted in 
a significant increase in tissue EPA levels as compared with control animals, and 
that this increase was about one-half of that seen when animals were fed EPA.  
SDA was also effectively converted and stored as DPA, as compared with control 
animals.  This increase was about two-thirds as effective as that demonstrated 
by the inclusion of EPA in the diet.  Neither EPA nor SDA provided by diet were 
metabolized to form DHA in the membrane phospholipids. These results are 
consistent with others that report either a lack of or very low conversion of either 
SDA or EPA to DHA[3;4].   This lack of conversion could be due either to the low 
level of activity of the ∆6 desaturase enzyme, or the presence of ALA in our basal 
US17 diet mix.  In mammalian cells the conversion of DPA to DHA is not a direct 
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one.  Instead, DPA is first metabolized by two rounds of elongation to form 24:5n-
3.  The ∆6 desaturase enzyme then desaturates 24:5n-3 to 24:6n-3.  The 24 
carbon chain length fatty acid is then shortened by β-oxidation to form DHA[5].  
This pathway is referred to as the “Sprecher pathway”.  The reaction rate of this 
pathway is slow, and it has been reported that DPA is preferentially used as a 
substrate for β-oxidation to form EPA rather than being metabolized to DHA[6].  
This may provide one possible explanation for the lack of DHA accumulation in 
liver phospholipids of our animals.  The presence of ALA in our basal US17 diet 
may provide an alternative explanation for the lack of significant increase in 
tissue DHA seen in animals fed EPA or SDA as compared with controls.  DHA 
plays an important role in formation of the cell membrane, and because of this 
shorter n-3 fatty acids are converted to DHA until the membranes become 
saturated, only then is it used to form EPA or DPA.  This leads to the possibility 
that our basal diets may have provided enough ALA to saturate the concentration 
of DHA in the cell membranes regardless of the addition of EPA or SDA.    
 Studies that suggest that the inclusion of n-3 fatty acids in the diet can 
have beneficial effects on health aspects from cardiovascular function to 
inflammation[7-9].  As previously mentioned the American Heart Association has 
recommended an increased intake of n-3 fatty acids as a means to reduce the 
risk for heart disease[10].  It has also been accepted that nutritional formulas 
containing n-3 fatty acids may be useful as therapeutics for critically ill patients in 
numerous disease states[11;12].  Most evidence for the benefits associated with 
n-3 fatty acids applies to the long-chain members of the n-3 family EPA and 
DHA, both of which occur in fish and fish oil.  Suggestions that patients or 
communities at large increase intake of fish are problematic for numerous 
reasons, including; consumption of contaminated fish, food related allergies, 
general resistance to dietary change, and limitations on natural fish stocks[8;13].    
Given the utility of n-3 fatty acids in human health and nutrition, identification of a 
suitable alternative source for dietary n-3 fatty acids is urgently required.   
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The use of the ∆6 desaturase precursor fatty acid ALA may be used as an 
alternative means to increase tissue EPA levels; however, the conversion from 
ALA to EPA is too inefficient to be a practical suggestion[4;14].   Conversion of 
ALA to EPA is a three step enzymatic process, and it has been suggested that 
the first step in this metabolism, the ∆6 desaturase enzyme, may be the rate 
limiting step in the conversion[15].  The inefficiency of this conversion process 
has driven an interest in the use of SDA, which is the fatty acid product of ∆6 
desaturase activity on ALA, as a possible source for increasing tissue EPA[4].  
Feeding oil blends containing SDA can efficiently increase membrane 
phospholipid n-3 content [3;16;17].  Studies in which SDA was added to cell 
culture also resulted in incorporation of EPA and DPA into cell membranes[18].   
As a result, agricultural companies have been working towards designing plant 
species that can produce high levels of SDA in their seeds in hopes of providing 
a sustainable alternative source for increasing tissue content of beneficial n-3 
fatty acids[19].     
Results from our current study confirm that addition of purified EPA ethyl 
esters to the diet can increase tissue content of EPA and DPA, but not DHA.  
These findings also demonstrate that dietary supplementation with SDA can 
significantly increase content of EPA and DPA, but not DHA in liver membrane 
phospholipids in a comparable fashion as animals fed a diet containing EPA.  
These findings suggest that dietary supplementation with SDA might provide a 
reasonable alternative to EPA provided by diet to increase the accumulation of 
beneficial n-3 fatty acids in tissue phospholipids.   
Animals were fed 200 kcal·kg-1·day-1 and diets were typically fully 
consumed by the following day.  Body weights were measured daily, and 
although it appears that there is a slight decrease in body weight for SDA fed 
animals as compared with the other dietary groups, this difference was not 
significant.  This was an interesting trend as SDA animals readily consumed their 
food, which rules out a dietary preference.  SDA animals also had similar starting 
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body weights, and there were no obvious physical differences among animals in 
this feeding group and those in the EPA and OA groups. 
In order to ensure that our experimental model was appropriate for 
detecting apoptosis we utilized two independent tests, TUNEL and gel 
electrophoresis, to look for presence of apoptotic bodies and hallmark DNA 
banding patterns, respectively.  Although not quantitative, our gel electrophoresis 
experiments provided evidence that cells were indeed undergoing apoptosis after 
20h, regardless of LPS treatment.  Prepared slides from all feeding groups 
contained bodies that fluoresce positively for TUNEL stain following 20h 
incubation.  Regardless of feeding group, slides containing cells that were 
incubated in presence of LPS appeared to posses fewer TUNEL positive bodies 
than their untreated counterparts.  Both of these tests provided evidence that  
cells were undergoing apoptosis.  Fluorescence microscopy also showed that 
LPS reduced apoptosis. 
Our results show that diet did not significantly affect neutrophil viability 
following 20h incubation in absence or presence of LPS.  LPS is a well known  
activator of neutrophils and increases neutrophil lifespan[20].   The lack of 
difference among dietary groups is not likely due to fault with LPS treatment, as 
we tested whether our LPS model was sufficient to induce changes in neutrophil 
lifespan, regardless of diet.   We found that, irrespective of diet, LPS increased 
neutrophil viability, and that this increase in viability was through a reduction in 
apoptosis, secondary necrosis, and cell death.  Furthermore, we found that in 
freshly extracted neutrophils, secondary necrosis and cell death appeared to be 
increased in the EPA group, but this increase failed to reach significance 
(p=0.053). Although, these effects were probably due to the small sample size 
and high variability, there is a close association between basal viability, 
apoptosis, secondary necrosis, and cell death.  Because of this association we 
normalized the data by calculating the absolute difference between basal 
neutrophils and those incubated for 20h in absence or presence of LPS.  We 
ensured that the calculation had not altered the LPS treatment by comparing the 
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results shown in Figure 4.5 (A-D) with those in Figure 4.6 (A-C).  Results from 
both figures showed that the addition of LPS resulted in decreased apoptosis, 
secondary necrosis, and cell death.  We found that the lack of dietary interaction 
was also probably not due to differences in basal neutrophils, as normalization 
did not produce any significant changes among dietary groups regarding 
neutrophil viability in absence or presence of LPS.  Analysis of normalized data 
revealed a trend towards an increase in viability in EPA and SDA animals as 
compared with OA animals.  Although this trend failed to attain significance 
(p=0.069), this could be a dietary effect, as power analysis suggested the 
possibility of a statistically significant increase in viability with the addition of 
approximately 15 animals.   
Despite numerous studies that demonstrate definitive health benefits from 
diets containing n-3 fatty acids, mainly attributed to EPA or DHA found in fish oil, 
and a large body of literature demonstrating the positive effects of n-3 PUFAs as 
therapeutic agents for inflammatory disorders, such as sepsis and ARDS, there 
is a growing concern in the literature regarding safety of feeding n-3 fatty acids 
as a means of controlling inflammation[21].  Several of these studies indicate that 
feeding high levels of n-3 fatty acids can lead to an immuno-compromised state 
by decreasing ability of the host to respond to infection[22;23].  PMNs play a vital 
role at maintaining host immunity, and have been described as being the first 
response to bacterial infection. Our current study may be of interest in light of 
these recent papers that have questioned the safety of dietary supplementation 
with n-3 PUFAs because of the potential to induce an immunocompromised 
condition in subjects[21].  Studies discussing the effect of n-3 fatty acids and 
immunosuppression have shown that long-term feeding (28d) of diets containing 
high levels of fish oil (18% by weight) leads to a diminished host response to 
bacterial challenge[22;23].    Our current findings show that EPA or SDA does 
not significantly alter neutrophil lifespan or LPS-mediated neutrophil survival.  
These findings show that 1% EPA or 1% SDA will not interfere with the ability of 
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neutrophils to increase cell survival in response to bacterial products such as 
LPS.     
One of the objectives of this study was to investigate the hypothesis that 
the beneficial effects of dietary supplementation with n-3 PUFAs observed by 
Mancuso et al[24] was due to an attenuation of LPS-mediated PMN survival.  
The increased rate of apoptosis would facilitate a faster clearance of 
inflammatory cells from pulmonary tissue, thereby attenuating PMN 
accumulation.  In this study SDA and EPA did not significantly increase PMN 
apoptosis or attenuate LPS mediated PMN survival.  Previous work by Gillis et 
al[25] suggested that diet might interact with cell viability by increasing apoptosis, 
and that this increase in apoptosis may be the reason for the muted PMN 
response observed in ARDS patients, and animal models of ALI previously 
described by our laboratory[25;26].  However, findings from our current study do 
not support this hypothesis.  There could be several reasons for the differences 
observed in our current work and previous results by Gillis et al[26].  First, HL-60 
cells are a promyelocytic human leukemia cell line that has been adapted for use 
as a model of PMN function[27] .  N-3 fatty acids such as EPA have been 
reported to have anti-tumorigenic properties, and decrease viability in a number 
of cell lines at least in vitro[1;28-32].  One review reports that in over 100 cancer 
cell lines, the addition of PUFAs to cell culture could reduce cell proliferation, or 
induce apoptosis, while having little or no effect on normal cells[33].  Thus, the 
increase in apoptosis observed in earlier studies from our laboratory may have 
been complicated by the anti-carcinogenic action of PUFAs.  Differences 
between the findings from this study and those previously reported could also be 
due to a difference in treatments.  HL-60 cell culture work from our lab was 
dependent on the addition of PUFAs directly to cell media.  This could also 
induce unanticipated effects as studies have reported that some of the cytotoxic 
effects of n-3 PUFAs may be due to the formation of lipid peroxidation products 
in vitro[34].       
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  These findings suggest that there may be other factors besides 
apoptosis involved in the beneficial effects observed in the studies by 
Mancuso[24]. A possible alternative mechanism for the reduction of PMN 
concentration in BAL fluid of ARDS patients fed nutritional formulas containing 
fish oil may be due to a reduced potential of alveolar macrophages to recruit 
circulating PMNs to pulmonary tissue by a reduction of LTB4 synthesis.  LTB4 has 
been shown to be a potent attractant of PMNs to pulmonary tissue[35].  It has 
also been shown that LTB4 is increased in the sputum of patients with COPD and 
ARDS, which results in an increased chemotactic potential for PMNs[36].  The 
importance of LTB4 as a signaling molecule in the lung is further emphasized by 
the fact the alveolar macrophages have been shown to be capable of an 
increased production of leukotrienes upon stimulation as compared with non-
alveolar macrophages and monocytes, and that alveolar macrophages 
preferentially produce leukotriene products of eicosanoid metabolism[37].  
Stimulated alveolar macrophages also preferentially metabolize EPA as 
compared with AA[38;39].  Previous work from our laboratory demonstrated a 
significant reduction of LTB4 concentrations in BAL fluid of animals and patients 
with ALI or ARDS fed nutritional formulas containing fish oil[24;40].   Reduction in 
LTB4 could lead to a decreased chemotactic potential of resident alveolar 
macrophages, resulting in a decreased influx of PMNs rather than an attenuated 
lifespan of recruited PMNs.   
 One of the limiting factors of our current study was that we only examined 
the effect of feeding 1% EPA or 1% SDA for 14 days.  For future studies it would 
be of interest to explore a dose-response of SDA and EPA on both membrane 
phospholipid profiles as well as PMN function.  Feeding fatty acids at different 
concentrations and for different lengths of time might help clarify the differences 
and similarities between SDA and EPA, and further strengthen the case for SDA 
as a substitute for dietary EPA.  An extension of current study conditions to 
include more animals in each feeding group may also elucidate whether diet 
supplemented with 1% EPA or 1% SDA is influencing PMN lifespan by 
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increasing PMN viability and LPS-mediated cell survival.    Given the importance 
of LTB4 in the sequestration of PMNs to pulmonary tissue, it would also be 
worthwhile to examine the chemotactic potential of alveolar macrophages 
following dietary supplementation with EPA and SDA, as well as the ability of 
PMNs with preloaded cell membranes to respond to chemotactic stimuli.   
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Part 6 
Conclusions
 
 152
I.  Conclusions 
 
Based on findings from these experiments it can be concluded first, that the diets 
supplemented with SDA ethyl ester increased EPA and DPA, but not DHA 
content in the liver.  These findings were similar to those observed in animals fed 
diets containing purified EPA ethyl ester, which increased membrane 
phospholipid concentrations of EPA and DPA, but not DHA in liver.  These 
findings lead to the acceptance of our first hypothesis that diets supplemented 
with purified SDA ethyl ester increased EPA content in liver phospholipids and 
the increase was similar to that observed in animals fed diets containing EPA 
ethyl ester.   
 It is concluded, second, from these findings that the addition of 1% EPA or 
1% SDA to the diet does not alter viability, apoptosis, secondary necrosis, or cell 
death in glycogen-elicited peritoneal neutrophils in absence or presence of LPS 
in the rat.  This leads us to reject our second hypothesis that dietary 
supplementation with SDA or EPA will impact the regulation of constitutive and 
LPS-induced survival in rat glycogen-elicited peritoneal neutrophils by influencing 
the rate of apoptosis in both cell states. 
 The significance of this study is that it provides evidence that dietary SDA 
provides an alternative to EPA as a means to increase the concentration of EPA 
and DPA in liver membrane phospholipids.  This study also provides evidence 
that the inclusion of 1% EPA or 1% SDA in the diet does not lead to an increase 
in constitutive neutrophil apoptosis and will not interfere with the ability of 
neutrophils to respond to bacterial endotoxin by increasing cell lifespan.  This 
indicates that the addition of 1% EPA and 1% SDA to a standard western diet will 
not lead to an immunocompromised state. 
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